Relative fracture risk in NICE meta-analysis
\\n\\n
Released this past November, the list is based on data collected from the Web of Science and highlights some of the world’s most influential scientific minds by naming the researchers whose publications over the previous decade have included a high number of Highly Cited Papers placing them among the top 1% most-cited.
\\n\\nWe wish to congratulate all of the researchers named and especially our authors on this amazing accomplishment! We are happy and proud to share in their success!
\\n"}]',published:!0,mainMedia:null},components:[{type:"htmlEditorComponent",content:'IntechOpen is proud to announce that 179 of our authors have made the Clarivate™ Highly Cited Researchers List for 2020, ranking them among the top 1% most-cited.
\n\nThroughout the years, the list has named a total of 252 IntechOpen authors as Highly Cited. Of those researchers, 69 have been featured on the list multiple times.
\n\n\n\nReleased this past November, the list is based on data collected from the Web of Science and highlights some of the world’s most influential scientific minds by naming the researchers whose publications over the previous decade have included a high number of Highly Cited Papers placing them among the top 1% most-cited.
\n\nWe wish to congratulate all of the researchers named and especially our authors on this amazing accomplishment! We are happy and proud to share in their success!
\n'}],latestNews:[{slug:"stanford-university-identifies-top-2-scientists-over-1-000-are-intechopen-authors-and-editors-20210122",title:"Stanford University Identifies Top 2% Scientists, Over 1,000 are IntechOpen Authors and Editors"},{slug:"intechopen-authors-included-in-the-highly-cited-researchers-list-for-2020-20210121",title:"IntechOpen Authors Included in the Highly Cited Researchers List for 2020"},{slug:"intechopen-maintains-position-as-the-world-s-largest-oa-book-publisher-20201218",title:"IntechOpen Maintains Position as the World’s Largest OA Book Publisher"},{slug:"all-intechopen-books-available-on-perlego-20201215",title:"All IntechOpen Books Available on Perlego"},{slug:"oiv-awards-recognizes-intechopen-s-editors-20201127",title:"OIV Awards Recognizes IntechOpen's Editors"},{slug:"intechopen-joins-crossref-s-initiative-for-open-abstracts-i4oa-to-boost-the-discovery-of-research-20201005",title:"IntechOpen joins Crossref's Initiative for Open Abstracts (I4OA) to Boost the Discovery of Research"},{slug:"intechopen-hits-milestone-5-000-open-access-books-published-20200908",title:"IntechOpen hits milestone: 5,000 Open Access books published!"},{slug:"intechopen-books-hosted-on-the-mathworks-book-program-20200819",title:"IntechOpen Books Hosted on the MathWorks Book Program"}]},book:{item:{type:"book",id:"6755",leadTitle:null,fullTitle:"Recent Advances in Arthroscopic Surgery",title:"Recent Advances in Arthroscopic Surgery",subtitle:null,reviewType:"peer-reviewed",abstract:'This book is aimed at providing an overview of arthroscopic joint surgery involving major joints in the body. It discusses all aspects of arthroscopy including complex surgical procedures, feasibility of performing surgery as an OPD procedure, and complications associated with these surgeries. The chapters are organised in regional basis and presented in an easy-to-understand format. This book will benefit all sports medicine physicians, orthopaedic surgeons and trainees, physiotherapists, and all clinicians involved in treating joint diseases. The combination of the authors\' shared experiences with facts and presentation of figures and photographs will help the reader in understanding the complex principles involved. This can be used as a text for an individual or a "must have" reference book for any medical library.',isbn:"978-1-78984-226-5",printIsbn:"978-1-78984-225-8",pdfIsbn:"978-1-83881-690-2",doi:"10.5772/intechopen.72480",price:119,priceEur:129,priceUsd:155,slug:"recent-advances-in-arthroscopic-surgery",numberOfPages:154,isOpenForSubmission:!1,isInWos:1,hash:"5c122c5b88bdc03c130d34ad2ac2d722",bookSignature:"Hiran Wimal Amarasekera",publishedDate:"October 10th 2018",coverURL:"https://cdn.intechopen.com/books/images_new/6755.jpg",numberOfDownloads:5005,numberOfWosCitations:2,numberOfCrossrefCitations:0,numberOfDimensionsCitations:1,hasAltmetrics:1,numberOfTotalCitations:3,isAvailableForWebshopOrdering:!0,dateEndFirstStepPublish:"December 11th 2017",dateEndSecondStepPublish:"January 8th 2018",dateEndThirdStepPublish:"March 2nd 2018",dateEndFourthStepPublish:"May 21st 2018",dateEndFifthStepPublish:"July 20th 2018",currentStepOfPublishingProcess:5,indexedIn:"1,2,3,4,5,6",editedByType:"Edited by",kuFlag:!1,editors:[{id:"67634",title:"Dr.",name:"Hiran",middleName:"Wimal",surname:"Amarasekera",slug:"hiran-amarasekera",fullName:"Hiran Amarasekera",profilePictureURL:"https://mts.intechopen.com/storage/users/67634/images/system/67634.jpg",biography:"Hiran Amarasekera is a Consultant Orthopaedic Surgeon from Sri Lanka currently working in University Hospitals of Coventry and Warwickshire, the UK as a hip preservation fellow. \r\nHis special interests include young adult hip and knee problems, sports injuries, Hip and knee arthroplasty, and complex arthroscopic procedures. \r\nHe completed the MBBS from Kasturba medical college Manipal, India and did his postgraduate in Trauma and Orthopaedics at the Post-graduate Institute of the Medicine University of Colombo obtained the MS. \r\nHe was initially trained at the National Hospital of Sri Lanka and then completed the further training at the Oldchurch Hospital in Essex UK and The Avenue Hospital Melbourne, Australia and University Hospitals of Coventry and Warwickshire, UK.\r\nHe obtained the FRCS from Royal College of Surgeons of Edinburgh in 2003 and was elected a fellow of Sri Lanka College of surgeons (FCSSL) 2012. \r\nHe has a keen interest in academia and research. Working as a clinical research fellow in Warwick Medical School he obtained the MPhil form University of Warwick and was elected for a research fellowship to University of California Los Angeles (UCLA). \r\nHis research interests include blood flow to the hip, failure of hip resurfacing, designing new hip prosthesis, and surgical approaches to the hip. \r\nHe has over 30 international publications and presentations and several book chapter. \r\nHe also works as a reviewer for international orthopedic journals and has reviewed over 35 papers and is a member of the editorial board of Sri Lanka Journal of Surgery.",institutionString:"University of Warwick Science Park",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"1",institution:{name:"University of Warwick Science Park",institutionURL:null,country:{name:"United Kingdom"}}}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,coeditorOne:null,coeditorTwo:null,coeditorThree:null,coeditorFour:null,coeditorFive:null,topics:[{id:"1150",title:"Orthopedics",slug:"orthopedics"}],chapters:[{id:"62871",title:"Successful Knee Arthroscopy: Techniques",doi:"10.5772/intechopen.79268",slug:"successful-knee-arthroscopy-techniques",totalDownloads:872,totalCrossrefCites:0,totalDimensionsCites:0,signatures:"Chia-Liang Ang",downloadPdfUrl:"/chapter/pdf-download/62871",previewPdfUrl:"/chapter/pdf-preview/62871",authors:[{id:"218149",title:"Dr.",name:"Chia Liang",surname:"Ang",slug:"chia-liang-ang",fullName:"Chia Liang Ang"}],corrections:null},{id:"61627",title:"Single-Bundle Anterior Cruciate Ligament Reconstruction",doi:"10.5772/intechopen.77338",slug:"single-bundle-anterior-cruciate-ligament-reconstruction",totalDownloads:1045,totalCrossrefCites:0,totalDimensionsCites:0,signatures:"Kavin Khatri, Darsh Goyal and Deepak Bansal",downloadPdfUrl:"/chapter/pdf-download/61627",previewPdfUrl:"/chapter/pdf-preview/61627",authors:[{id:"232328",title:"Dr.",name:"Kavin",surname:"Khatri",slug:"kavin-khatri",fullName:"Kavin Khatri"}],corrections:null},{id:"61094",title:"Anatomic Single-Bundle ACL Reconstruction with Remnant Augmentation Technique",doi:"10.5772/intechopen.76577",slug:"anatomic-single-bundle-acl-reconstruction-with-remnant-augmentation-technique",totalDownloads:457,totalCrossrefCites:0,totalDimensionsCites:0,signatures:"Adinun Apivatgaroon",downloadPdfUrl:"/chapter/pdf-download/61094",previewPdfUrl:"/chapter/pdf-preview/61094",authors:[{id:"238107",title:"Dr.",name:"Adinun",surname:"Apivatgaroon",slug:"adinun-apivatgaroon",fullName:"Adinun Apivatgaroon"}],corrections:null},{id:"61200",title:"Office-Based Small Bore Needle Arthroscopy of the Knee",doi:"10.5772/intechopen.76757",slug:"office-based-small-bore-needle-arthroscopy-of-the-knee",totalDownloads:365,totalCrossrefCites:0,totalDimensionsCites:0,signatures:"Kyle Williams, Kelly Scott, Donald Dulle III and Anikar Chhabra",downloadPdfUrl:"/chapter/pdf-download/61200",previewPdfUrl:"/chapter/pdf-preview/61200",authors:[{id:"240647",title:"Dr.",name:"Anikar",surname:"Chhabra",slug:"anikar-chhabra",fullName:"Anikar Chhabra"},{id:"248852",title:"Mr.",name:"Kyle",surname:"Williams",slug:"kyle-williams",fullName:"Kyle Williams"},{id:"248853",title:"Mr.",name:"Donald",surname:"Dulle",slug:"donald-dulle",fullName:"Donald Dulle"},{id:"248854",title:"Dr.",name:"Kelly",surname:"Scott",slug:"kelly-scott",fullName:"Kelly Scott"}],corrections:null},{id:"61733",title:"Arthroscopic Technique to Treat Articular Cartilage Lesions in the Patellofemoral Joint",doi:"10.5772/intechopen.76617",slug:"arthroscopic-technique-to-treat-articular-cartilage-lesions-in-the-patellofemoral-joint",totalDownloads:438,totalCrossrefCites:0,totalDimensionsCites:0,signatures:"Anell Olivos-Meza, Antonio Madrazo-Ibarra and Clemente Ibarra\nPonce de León",downloadPdfUrl:"/chapter/pdf-download/61733",previewPdfUrl:"/chapter/pdf-preview/61733",authors:[{id:"239055",title:"Ph.D.",name:"Clemente",surname:"Ibarra",slug:"clemente-ibarra",fullName:"Clemente Ibarra"},{id:"240588",title:"Dr.",name:"Anell",surname:"Olivos-Meza",slug:"anell-olivos-meza",fullName:"Anell Olivos-Meza"},{id:"240589",title:"Dr.",name:"Antonio",surname:"Madrazo Ibarra",slug:"antonio-madrazo-ibarra",fullName:"Antonio Madrazo Ibarra"}],corrections:null},{id:"63657",title:"Subscapularis Tendon Tears: Classification, Diagnosis and Repair",doi:"10.5772/intechopen.77349",slug:"subscapularis-tendon-tears-classification-diagnosis-and-repair",totalDownloads:652,totalCrossrefCites:0,totalDimensionsCites:0,signatures:"Laurent Baverel",downloadPdfUrl:"/chapter/pdf-download/63657",previewPdfUrl:"/chapter/pdf-preview/63657",authors:[{id:"239033",title:"M.D.",name:"Laurent",surname:"Baverel",slug:"laurent-baverel",fullName:"Laurent Baverel"}],corrections:null},{id:"60890",title:"Diagnosis and Treatment of the Meso-Acromion of the Shoulder",doi:"10.5772/intechopen.76267",slug:"diagnosis-and-treatment-of-the-meso-acromion-of-the-shoulder",totalDownloads:401,totalCrossrefCites:0,totalDimensionsCites:0,signatures:"William B. Stetson, Stephanie Morgan, Brian Chung, Nicole Hung,\nGenevieve Mazza and Alex McIntyre",downloadPdfUrl:"/chapter/pdf-download/60890",previewPdfUrl:"/chapter/pdf-preview/60890",authors:[{id:"240028",title:"Dr.",name:"William",surname:"Stetson",slug:"william-stetson",fullName:"William Stetson"},{id:"240029",title:"BSc.",name:"Brian",surname:"Chung",slug:"brian-chung",fullName:"Brian Chung"},{id:"240030",title:"B.Sc.",name:"Nicole",surname:"Hung",slug:"nicole-hung",fullName:"Nicole Hung"},{id:"240032",title:"BSc.",name:"Alex",surname:"McIntyre",slug:"alex-mcintyre",fullName:"Alex McIntyre"},{id:"242309",title:"BSc.",name:"Stephanie",surname:"Morgan",slug:"stephanie-morgan",fullName:"Stephanie Morgan"},{id:"242310",title:"BSc.",name:"Genevieve",surname:"Mazza",slug:"genevieve-mazza",fullName:"Genevieve Mazza"}],corrections:null},{id:"61227",title:"Hip Arthroscopy Made Simple, Easy, and Elegant. A Novel Variant of the Outside-In Technique",doi:"10.5772/intechopen.77047",slug:"hip-arthroscopy-made-simple-easy-and-elegant-a-novel-variant-of-the-outside-in-technique",totalDownloads:387,totalCrossrefCites:0,totalDimensionsCites:1,signatures:"Antonio Porthos Salas, John M. O’Donnell and Jacek Macek",downloadPdfUrl:"/chapter/pdf-download/61227",previewPdfUrl:"/chapter/pdf-preview/61227",authors:[{id:"239187",title:"Dr.",name:"Antonio Porthos",surname:"Salas",slug:"antonio-porthos-salas",fullName:"Antonio Porthos Salas"}],corrections:null},{id:"60318",title:"Neurological Complications of Elbow Arthroscopy",doi:"10.5772/intechopen.75594",slug:"neurological-complications-of-elbow-arthroscopy",totalDownloads:389,totalCrossrefCites:0,totalDimensionsCites:0,signatures:"William B. Stetson, Kevin Vogeli, Brian Chung, Nicole J. Hung,\nStephanie Morgan and Milan Stevanovic",downloadPdfUrl:"/chapter/pdf-download/60318",previewPdfUrl:"/chapter/pdf-preview/60318",authors:[{id:"240028",title:"Dr.",name:"William",surname:"Stetson",slug:"william-stetson",fullName:"William Stetson"},{id:"240029",title:"BSc.",name:"Brian",surname:"Chung",slug:"brian-chung",fullName:"Brian Chung"},{id:"240030",title:"B.Sc.",name:"Nicole",surname:"Hung",slug:"nicole-hung",fullName:"Nicole Hung"},{id:"242309",title:"BSc.",name:"Stephanie",surname:"Morgan",slug:"stephanie-morgan",fullName:"Stephanie Morgan"},{id:"243613",title:"Dr.",name:"Kevin",surname:"Vogeli",slug:"kevin-vogeli",fullName:"Kevin Vogeli"},{id:"243615",title:"Dr.",name:"Milan",surname:"Stevanovic",slug:"milan-stevanovic",fullName:"Milan Stevanovic"}],corrections:null}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}},relatedBooks:[{type:"book",id:"938",title:"Recent Advances in Arthroplasty",subtitle:null,isOpenForSubmission:!1,hash:"617e868a5450ec0c9d233121177ca61e",slug:"recent-advances-in-arthroplasty",bookSignature:"Samo K. Fokter",coverURL:"https://cdn.intechopen.com/books/images_new/938.jpg",editedByType:"Edited by",editors:[{id:"68181",title:"Dr.",name:"Samo",surname:"Fokter",slug:"samo-fokter",fullName:"Samo Fokter"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3394",title:"Arthroplasty",subtitle:"Update",isOpenForSubmission:!1,hash:"672aa53986638f5846f76ee8c8a1ea9e",slug:"arthroplasty-update",bookSignature:"Plamen Kinov",coverURL:"https://cdn.intechopen.com/books/images_new/3394.jpg",editedByType:"Edited by",editors:[{id:"64690",title:"Prof.",name:"Plamen",surname:"Kinov",slug:"plamen-kinov",fullName:"Plamen Kinov"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"2088",title:"Recent Advances in Scoliosis",subtitle:null,isOpenForSubmission:!1,hash:"83cd4ebc741a8c3eb6dd08e5a6957181",slug:"recent-advances-in-scoliosis",bookSignature:"Theodoros B. Grivas",coverURL:"https://cdn.intechopen.com/books/images_new/2088.jpg",editedByType:"Edited by",editors:[{id:"35180",title:"Dr.",name:"Theodoros",surname:"Grivas",slug:"theodoros-grivas",fullName:"Theodoros Grivas"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"5164",title:"Advanced Techniques in Bone Regeneration",subtitle:null,isOpenForSubmission:!1,hash:"e99f852544eefac23fb5fe0697c2096d",slug:"advanced-techniques-in-bone-regeneration",bookSignature:"Alessandro Rozim Zorzi and Joao Batista de Miranda",coverURL:"https://cdn.intechopen.com/books/images_new/5164.jpg",editedByType:"Edited by",editors:[{id:"80871",title:"M.D.",name:"Alessandro Rozim",surname:"Zorzi",slug:"alessandro-rozim-zorzi",fullName:"Alessandro Rozim Zorzi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"2012",title:"Recent Advances in Hip and Knee Arthroplasty",subtitle:null,isOpenForSubmission:!1,hash:"20ffb4ff9f89a7537b335291c94cda13",slug:"recent-advances-in-hip-and-knee-arthroplasty",bookSignature:"Samo K. Fokter",coverURL:"https://cdn.intechopen.com/books/images_new/2012.jpg",editedByType:"Edited by",editors:[{id:"68181",title:"Dr.",name:"Samo",surname:"Fokter",slug:"samo-fokter",fullName:"Samo Fokter"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"535",title:"Achilles Tendon",subtitle:null,isOpenForSubmission:!1,hash:"afb551afd8adf63d63a7c0a2b9513652",slug:"achilles-tendon",bookSignature:"Andrej Čretnik",coverURL:"https://cdn.intechopen.com/books/images_new/535.jpg",editedByType:"Edited by",editors:[{id:"91518",title:"Prof.",name:"Andrej",surname:"Cretnik",slug:"andrej-cretnik",fullName:"Andrej Cretnik"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"640",title:"Modern Arthroscopy",subtitle:null,isOpenForSubmission:!1,hash:"ad9afcdcfadbb0f3150016589356d633",slug:"modern-arthroscopy",bookSignature:"Jason L. Dragoo",coverURL:"https://cdn.intechopen.com/books/images_new/640.jpg",editedByType:"Edited by",editors:[{id:"77223",title:"Dr",name:"Jason L.",surname:"Dragoo",slug:"jason-l.-dragoo",fullName:"Jason L. Dragoo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"5724",title:"Frailty and Sarcopenia",subtitle:"Onset, Development and Clinical Challenges",isOpenForSubmission:!1,hash:"3bddbdef3183cb7745a66525d1f93515",slug:"frailty-and-sarcopenia-onset-development-and-clinical-challenges",bookSignature:"Yannis Dionyssiotis",coverURL:"https://cdn.intechopen.com/books/images_new/5724.jpg",editedByType:"Edited by",editors:[{id:"76883",title:"PhD.",name:"Yannis",surname:"Dionyssiotis",slug:"yannis-dionyssiotis",fullName:"Yannis Dionyssiotis"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"756",title:"Orthopedic Surgery",subtitle:null,isOpenForSubmission:!1,hash:"e33b92ab0447186525dd0440e3f03606",slug:"orthopedic-surgery",bookSignature:"Zaid Al-Aubaidi and Andreas Fette",coverURL:"https://cdn.intechopen.com/books/images_new/756.jpg",editedByType:"Edited by",editors:[{id:"63333",title:"Dr",name:"Zaid",surname:"Al-Aubaidi",slug:"zaid-al-aubaidi",fullName:"Zaid Al-Aubaidi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"5228",title:"Pain Management",subtitle:null,isOpenForSubmission:!1,hash:"fff27606077f643a636f40d3bff7757b",slug:"pain-management",bookSignature:"Milica Prostran",coverURL:"https://cdn.intechopen.com/books/images_new/5228.jpg",editedByType:"Edited by",editors:[{id:"43919",title:"Prof.",name:"Milica",surname:"Prostran",slug:"milica-prostran",fullName:"Milica Prostran"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],ofsBooks:[]},correction:{item:{id:"73131",slug:"corrigendum-to-advancement-of-nitrogen-fertilization-on-tropical-environmental",title:"Corrigendum to: Advancement of Nitrogen Fertilization on Tropical Environmental",doi:null,correctionPDFUrl:"https://cdn.intechopen.com/pdfs/73131.pdf",downloadPdfUrl:"/chapter/pdf-download/73131",previewPdfUrl:"/chapter/pdf-preview/73131",totalDownloads:null,totalCrossrefCites:null,bibtexUrl:"/chapter/bibtex/73131",risUrl:"/chapter/ris/73131",chapter:{id:"71453",slug:"advancement-of-nitrogen-fertilization-on-tropical-environmental",signatures:"Elizeu Monteiro Pereira Junior, Elaine Maria Silva Guedes Lobato, Beatriz Martineli Lima, Barbara Rodrigues Quadros, Allan Klynger da Silva Lobato, Izabelle Pereira Andrade and Letícia de Abreu Faria",dateSubmitted:"October 21st 2019",dateReviewed:"November 28th 2019",datePrePublished:"March 25th 2020",datePublished:"April 8th 2020",book:{id:"8004",title:"Nitrogen Fixation",subtitle:null,fullTitle:"Nitrogen Fixation",slug:"nitrogen-fixation",publishedDate:"April 8th 2020",bookSignature:"Everlon Cid Rigobelo and Ademar Pereira Serra",coverURL:"https://cdn.intechopen.com/books/images_new/8004.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"39553",title:"Prof.",name:"Everlon",middleName:"Cid",surname:"Rigobelo",slug:"everlon-rigobelo",fullName:"Everlon Rigobelo"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}},authors:[{id:"158046",title:"Dr.",name:"Elaine Maria Silva Guedes",middleName:"Guedes",surname:"Lobato",fullName:"Elaine Maria Silva Guedes Lobato",slug:"elaine-maria-silva-guedes-lobato",email:"elaine.guedes@ufra.edu.br",position:null,institution:null},{id:"313880",title:"Dr.",name:"Barbara",middleName:null,surname:"Rodrigues Quadros",fullName:"Barbara Rodrigues Quadros",slug:"barbara-rodrigues-quadros",email:"barbara.quadros@ufra.edu.br",position:null,institution:null},{id:"313881",title:"Dr.",name:"Izabelle",middleName:null,surname:"Pereira Andrade",fullName:"Izabelle Pereira Andrade",slug:"izabelle-pereira-andrade",email:"izabelle.andrade@ufra.edu.br",position:null,institution:null},{id:"314476",title:"Dr.",name:"Allan Klynger Da Silva",middleName:null,surname:"Lobato",fullName:"Allan Klynger Da Silva Lobato",slug:"allan-klynger-da-silva-lobato",email:"allan.lobato@ufra.edu.br",position:null,institution:{name:"Universidade Federal Rural da Amazônia",institutionURL:null,country:{name:"Brazil"}}},{id:"314477",title:"Dr.",name:"Leticia Abreu",middleName:null,surname:"Faria",fullName:"Leticia Abreu Faria",slug:"leticia-abreu-faria",email:"leticia.faria@ufra.edu.br",position:null,institution:{name:"Universidade Federal Rural da Amazônia",institutionURL:null,country:{name:"Brazil"}}},{id:"314484",title:"Mr.",name:"Elizeu Monteiro Pereira",middleName:null,surname:"Junior",fullName:"Elizeu Monteiro Pereira Junior",slug:"elizeu-monteiro-pereira-junior",email:"ta.elizeujr@gmail.com",position:null,institution:{name:"Universidade Federal Rural da Amazônia",institutionURL:null,country:{name:"Brazil"}}},{id:"314489",title:"Ms.",name:"Beatriz Martinelli",middleName:null,surname:"Lima",fullName:"Beatriz Martinelli Lima",slug:"beatriz-martinelli-lima",email:"biamartinelli13@gmail.com",position:null,institution:{name:"Universidade Federal Rural da Amazônia",institutionURL:null,country:{name:"Brazil"}}}]}},chapter:{id:"71453",slug:"advancement-of-nitrogen-fertilization-on-tropical-environmental",signatures:"Elizeu Monteiro Pereira Junior, Elaine Maria Silva Guedes Lobato, Beatriz Martineli Lima, Barbara Rodrigues Quadros, Allan Klynger da Silva Lobato, Izabelle Pereira Andrade and Letícia de Abreu Faria",dateSubmitted:"October 21st 2019",dateReviewed:"November 28th 2019",datePrePublished:"March 25th 2020",datePublished:"April 8th 2020",book:{id:"8004",title:"Nitrogen Fixation",subtitle:null,fullTitle:"Nitrogen Fixation",slug:"nitrogen-fixation",publishedDate:"April 8th 2020",bookSignature:"Everlon Cid Rigobelo and Ademar Pereira Serra",coverURL:"https://cdn.intechopen.com/books/images_new/8004.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"39553",title:"Prof.",name:"Everlon",middleName:"Cid",surname:"Rigobelo",slug:"everlon-rigobelo",fullName:"Everlon Rigobelo"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}},authors:[{id:"158046",title:"Dr.",name:"Elaine Maria Silva Guedes",middleName:"Guedes",surname:"Lobato",fullName:"Elaine Maria Silva Guedes Lobato",slug:"elaine-maria-silva-guedes-lobato",email:"elaine.guedes@ufra.edu.br",position:null,institution:null},{id:"313880",title:"Dr.",name:"Barbara",middleName:null,surname:"Rodrigues Quadros",fullName:"Barbara Rodrigues Quadros",slug:"barbara-rodrigues-quadros",email:"barbara.quadros@ufra.edu.br",position:null,institution:null},{id:"313881",title:"Dr.",name:"Izabelle",middleName:null,surname:"Pereira Andrade",fullName:"Izabelle Pereira Andrade",slug:"izabelle-pereira-andrade",email:"izabelle.andrade@ufra.edu.br",position:null,institution:null},{id:"314476",title:"Dr.",name:"Allan Klynger Da Silva",middleName:null,surname:"Lobato",fullName:"Allan Klynger Da Silva Lobato",slug:"allan-klynger-da-silva-lobato",email:"allan.lobato@ufra.edu.br",position:null,institution:{name:"Universidade Federal Rural da Amazônia",institutionURL:null,country:{name:"Brazil"}}},{id:"314477",title:"Dr.",name:"Leticia Abreu",middleName:null,surname:"Faria",fullName:"Leticia Abreu Faria",slug:"leticia-abreu-faria",email:"leticia.faria@ufra.edu.br",position:null,institution:{name:"Universidade Federal Rural da Amazônia",institutionURL:null,country:{name:"Brazil"}}},{id:"314484",title:"Mr.",name:"Elizeu Monteiro Pereira",middleName:null,surname:"Junior",fullName:"Elizeu Monteiro Pereira Junior",slug:"elizeu-monteiro-pereira-junior",email:"ta.elizeujr@gmail.com",position:null,institution:{name:"Universidade Federal Rural da Amazônia",institutionURL:null,country:{name:"Brazil"}}},{id:"314489",title:"Ms.",name:"Beatriz Martinelli",middleName:null,surname:"Lima",fullName:"Beatriz Martinelli Lima",slug:"beatriz-martinelli-lima",email:"biamartinelli13@gmail.com",position:null,institution:{name:"Universidade Federal Rural da Amazônia",institutionURL:null,country:{name:"Brazil"}}}]},book:{id:"8004",title:"Nitrogen Fixation",subtitle:null,fullTitle:"Nitrogen Fixation",slug:"nitrogen-fixation",publishedDate:"April 8th 2020",bookSignature:"Everlon Cid Rigobelo and Ademar Pereira Serra",coverURL:"https://cdn.intechopen.com/books/images_new/8004.jpg",licenceType:"CC BY 3.0",editedByType:"Edited by",editors:[{id:"39553",title:"Prof.",name:"Everlon",middleName:"Cid",surname:"Rigobelo",slug:"everlon-rigobelo",fullName:"Everlon Rigobelo"}],productType:{id:"1",title:"Edited Volume",chapterContentType:"chapter",authoredCaption:"Edited by"}}},ofsBook:{item:{type:"book",id:"10499",leadTitle:null,title:"Next - generation Greenhouses",subtitle:null,reviewType:"peer-reviewed",abstract:"\r\n\tGreenhouse cultivation has evolved from simple covered rows of open-fields crops to highly sophisticated controlled environment agriculture facilities that projected the image of plant factories for urban agriculture. The advances and improvements in greenhouse technology have promoted scientific solutions for the efficient production of plants in populated cities and multi-story buildings. Successful deployment of high-tech greenhouses for urban agriculture requires many components and subsystems, as well as the understanding of the external influencing factors that should be systematically considered and integrated.
\r\n\r\n\tThis book project aims to highlight some of the most recent advances in modern greenhouse technology for food security and the sustainability of crop production. Each chapter is expected to raise the awareness for technology transfer in advanced controlled environment agriculture, which is necessary for a successful transition to urban agriculture. Contributing chapters will highlight several aspects of a high-tech closed-field plant production system including improvements in the frame and covering materials, environment perception and data sharing, and advanced microclimate control and energy optimization models. In addition, the book will highlight urban agriculture and its derivatives, including vertical farming, rooftop greenhouses, and plant factories which are the extensions of CEA and have emerged as a response to the growing population, environmental degradation, and urbanization that are threatening food security. Finally, several opportunities and challenges will be identified as a summary chapter to show how integrated controlled environment agriculture can be implemented as vertical farming for urban agriculture.
\r\n\t
Osteoporosis can be divided into two principle strands, clinical osteoporosis and densitometric osteoporosis. Clinical osteoporosis involves the identification of a fragility fracture and does not need densitometry for treatment to begin. Densitometric osteoporosis is identified via an assessment of bone mineral density. Approaches to treatment depend on the global fracture risk and the outcomes of densitometric tests.
The initial stage of the pharmacological treatment of osteoporosis is to identify the pathology of the primary condition or to determine whether the loss of bone density is a secondary symptom of a separate condition. Where secondary osteoporosis is identified, priority is given to the treatment of the primary condition. The option of pharmacological therapy must only be contemplated if the risk of fracture is too elevated, given that the intention behind pharmacological treatment in osteoporosis is to reduce the fracture risk. Based on World Health Organization figures, less than half of patients presenting a fragility fracture have been diagnosed with densitometric osteoporosis [1]. Once a course of medication has begun, long-term management must address improvements to lifestyle and take aspects of, security, cost, and compliance into account. As such, it is absolutely necessary to assess and make determinations on the basis of cost, assessment of cost-efficiency, and the adaptability of patients to drug security.
Calcitonin binds to osteoclasts and hinders bone resorption. The use of salmon calcitonin has previously been widespread as a result of its extreme potency in humans, a result of its greater affinity for the human calcitonin receptor.
Calcitonin is now no longer a treatment for osteoporosis, having been supplanted by other treatments. Following a European risk-benefit analysis, the scientific committee of the European Medicines Agency (CHMP) advised that treatments using calcitonin should only be deployed in short-term scenarios.. Treatments using injectable calcitonin should be confined to the short-term in Paget\'s disease, the prevention of acute bone loss as a result of sudden immobilization and hypercalcemia resulting from cancer. In addition to this, calcitonin has been proven to be effective in treating pain resulting from fractures of the vertebral column. [2-4]
HRT is a form of treatment which deploys varying doses of estrogen, sometimes on its own, sometimes in combination with progestagens. The calculated risk of fracture, based on principal cohort trials of postmenopausal women treated with HRT over the long term, indicate an appreciable lowering of the likelihood of both vertebral fracture (RR=0.6; CI 95%: 0.36 to 0.99) and wrist fracture (RR=0.39; CI 95%: 0.24 to 0.64), but a non-significant lowering of the likelihood of hip fracture (RR=0.64; CI 95%: 0.32 to 1.04). The WHI trial (Women\'s Health Initiative), a randomised clinical trial (RCT) that assessed postmenopausal women randomly assigned to combined HRT (combined equine estrogen 0.625mg daily plus medroxyprogesterone 2.5mg daily) or a placebo, recorded, following 5.2 years of treatment, a decrease in hip fracture risk of 34% (hazard ratio [HR]=0.66; CI 95%: 0.45 to 0.98), in clinical vertebral fractures of 34% (HR=0.66; CI 95%: 0.44 to 0.98) and in any fracture of 24% (HR=0.76; CI 95%: 0.69 to 0.85) [5,6]. In the same investigation, the cohort taking estrogen on its own demonstrated comparable outcomes, however the treatment was put on hold as a result of an adverse risk-benefit ratio. In two meta-analyses of RCT’s, a decrease of 27% (RR=0.73; CI 95%: 0.56 to 0.94) in non-vertebral fractures and a trend towards a reduction of vertebral fractures (RR=0.66; CI 95%: 0.41 to 1.07) was recorded [7]. Nonetheless, neither the HERS (The Heart and Estrogen + Progestin Replacement Study) RCT nor the subsequent group, the HERS II study (Hulley et al., 1998), were able to register a decrease of the risk of hip fractures or of other locations (RR=1.04; CI 95%: 0.87 to 1.25) in patients with a history of cardiovascular disease [8].
The British National Institute of Health and Clinical Excellence published a meta-analysis of RCTs on HRT efficacy (with estrogen alone or combined) compared with placebo/non-treatment in postmenopausal women or those with surgical menopause [9]. The outcomes were organised according to the location of the fracture and the RCT used as the basis for the calculation of the relative risk was also identified. The outcomes are outlined in table 1.
\n\t\t\t\tFracture Location\n\t\t\t | \n\t\t\t\n\t\t\t\tNr of RCTs\n\t\t\t | \n\t\t\t\n\t\t\t\tn\n\t\t\t | \n\t\t\t\n\t\t\t\tRESULTS\n\t\t\t | \n\t\t\t\n\t\t\t\tReferences\n\t\t\t | \n\t\t
Vertebral fracture | \n\t\t\t4 RCTs | \n\t\t\t11,842 | \n\t\t\tRR=0.55; CI 95%: 0.46 to 0.66 | \n\t\t\t[10-13] | \n\t\t
Non-vertebral fracture | \n\t\t\t3 RCTs | \n\t\t\t11,774 | \n\t\t\tRR=0.73; CI 95%: 0.65 to 0.81 | \n\t\t\t[10, 11,14] | \n\t\t
Hip fracture | \n\t\t\t2 RCTs | \n\t\t\t11,745 | \n\t\t\tRR=0.63; CI 95%: 0.42 to 0.93 | \n\t\t\t[11,14] | \n\t\t
Any type of fracture | \n\t\t\t3 RCTs | \n\t\t\t11,556 | \n\t\t\tRR=0.70; CI 95%: 0.63 to 0.78 | \n\t\t\t[14-16] | \n\t\t
Relative fracture risk in NICE meta-analysis
A thorough and methodical review of five RCTs looking at HRT with estrogen and two looking at combined HRT estrogen plus progesterone, failed to display compelling variance in the occurrence of acute coronary events (including acute myocardial infarction) between the cohort subject to intervention and the control cohort [7]. A combination of the outcomes of three studies contrasting estrogenic therapy to a placebo [11, 17] reported an odds ratio (OR) of 1.34 (IC 95%: 1.07 to 1.68) for cerebral vascular events. The combined outcomes of the studies that contrasted estrogen plus progesterone combined treatment with a placebo [5, 18], indicated an elevated risk of ictus (OR=1.28; CI 95%: 1.05 to 1.57) in the cohort subject to intervention. Out of four thorough and methodical reviews of observational trials looking at women treated with HRT [19-22], three of these indicated a significant decrease in the global mortality risk for acute coronary events. A recently published, thorough and methodical review, that compensated for selection bias of inclusion and analysis, did not reveal any link between the THS and the incidence, and mortality of acute coronary events [22].
The WHI primary prevention trial indicated a distinct elevation of the risk of acute coronary events (41%), starting the second year of treatment (29 instances in the treatment cohort, compared with 21 instances for 10,000 women per year in the general population) [5]. This elevated risk was greater in non-mortal coronary incidents (RR=1.50; CI 95%: 1.08 to 2.08) than in the mortal coronary incidents (RR=1.20; CI 95%: 0.58 to 2.50). The RCTs of HRT with estrogens alone, in both primary and secondary prevention, failed to indicate any positive impact on cerebrovascular illness [23]. In addition, the WHI study cohort with estrogen indicated an elevated risk of cerebrovascular incidents.
In a thorough and methodical review, McLean et al. indicated that estrogen patients treated with estrogen demonstrate an elevated risk of major venous thromboembolic incidents (OR=1.36; CI 95%: 1.01 to 1.86) compared to the placebo cohort [7]. A further thorough and methodical review assessing the impact of HRT (estrogen with or without progestagens) encompassed 12 studies (3 RCTs, 8 case-control studies and 1 cohort study) and indicated an elevated risk of thromboembolism (RR=2.14; CI 95%: 1.64 to 2.81). This risk was elevated in the first two years of the therapy and it varied according to the dose [24].
A thorough and methodical review of 4 RCTs proved that patients treated with estrogens alone have a lower risk of breast cancer (OR=0.79; CI 95%: 0.66 to 0.93) than those treated with the placebo [7]. On the other hand, patients treated with estrogen and progestin have a higher risk of breast cancer (OR=1.28; CI 95%: 1.03 to 1.60) than those treated with the placebo [5, 18, 24].
Nonetheless the combined HRT cohort of the WHI study presented an elevated risk of invasive breast cancer [5]. This elevated risk occurred following the fourth year of treatment (RR=1.26; CI 95 %: 1.0 to 1.59), with a propensity to rise in line with the treatment’s longevity (38 instances compared with 30 for 10,000 women per year).
The treatment of estrogen alone elevates the risk of subsequent endometrial hyperplasia and cancer [25,26]. A meta-analysis including 29 observational studies reported a demonstrable elevation of the risk of endometrial cancer, with or without combined estrogens (RR=2.3; CI 95%: 2.1 to 2.5) [20]. This risk is directly related to the treatment’s longevity and continues to be raised for a maximum of 5 years or more following the termination of treatment.
Recently published thorough and methodical reviews of observational trials indicate an elevated incidence of ovarian cancer amongst women undergoing treatment, particularly long-term therapies (more than 10 years) [28,28]. Two cohort trials of postmenopausal women who underwent treatment for a period of more than 10 years corroborate this elevated risk of ovarian cancer (RR=2.2; CI 95%: 1.53 to 3.17), as well as an elevated mortality risk (RR=1.59; CI 95%: 1.13 to 2.25) [29, 30].
We can conclude that HRT is an effective therapy both for postmenopausal osteoporosis and for the management of fracture risk. Nevertheless, even taking this conclusion into account, the use of combined HRT is not recommeneded for periods greater than 5 years, given the possible risk factors linked with treatments using a daily dose equivalent to 50 pg of estradiol. When HRT treatment is indicated, it should be prescribed at a low dosage (equivalent to estrogen transdermal patches of 25 mcg), only using higher doses if it is absolutely essential to do so. Estrogens and progestagens are only advised for the treatment of women with intact uteri. The level of the progestagen dose should be determined on the basis of the estrogen dose. In instances where a hysterectomy was carried out as a result of endometrial cancer, HRT should not involve combined estrogen and progestagens. Continuous combined HRT treatment should only commence following one whole year of menopause.
Selective estrogen receptor modulators are medications with a selective impact on the estrogen receptor. They can function as estrogen receptor (ER) agonists in some tissues while in other tissues functioning as estrogen receptor antagonists. As a result of their selective estrogen-agonist behaviour within a variety of tissues, SERMs may be indicated as an alternative option for the prevention or treatment of conditions like osteoporosis, which are the result of a deficiency of estrogen, where avoiding the negatives effects of estrogens is a priority.
At present there are two forms of SERM, which are distinguished by their chemical structure: triphenylethylene derivatives, for example tamoxifen and toremifene, and benzothiophene derivatives, for example raloxifene and bazedoxifene. Tamoxifen and toremifene on the one hand are indicated for use in the treatment of breast cancer. Raloxifene on the other hand is used for the prevention and treatment of osteoporosis and in addition the prevention of breast cancer. All SERMs have been linked with an elevated occurrence of pulmonary thromboembolism and with the start of hot flushes, however they also impact in a positive manner on the lipid profile.
The SERMs vary distinctively with regards to tissue specificity. Bazedoxifene appears to have a lower impact on the uterus than estradiol jointly with raloxifene in animal experiments as a result of reduced estrogen receptor alpha agonistic effects.
Raloxifene acts as estrogen agonist in bone and other systems but not in reproductive tissue. Many trials have proved the effectiveness of raloxifene for preserving bone in the early postmenopausal phase. In a meta-analysis of seven studies (four treatment and three prevention studies) which looked at the impact of raloxifene versus a placebo on bone mineral density, raloxifene augmented bone mineral density within the lumbar spine following a two year period of treatment [31]. A trial of 601 women, five years following the menopause, who were given a daily dose of 30, 60 or 150mg of raloxifene over two years, indicated an augmentation of their bone mineral density in spine and hip, whereas those subjected to the placebo presented reduced bone mineral density in the same locations [32]. In contrast with the results from the placebo, the average alteration in BMD with 60mg of raloxifene was 2.4% in the spine and 2.4% at the total hip (p<0.001 versus placebo). Postmenopausal women presenting low bone mass and osteoporosis were monitored over eight years in the study entitled ‘Multiple Outcomes of Raloxifene Evaluation’ (MORE, n=7,705) and its sister trial entitled ‘Continuing Outcomes Relevant to Evista’ (CORE, n=4,011) [33]. In relation to fractures, whilst raloxifene treatment led to a decreased risk of vertebral fracture, it failed to demonstrate a reduced risk of non-vertebral fractures. Nevertheless, in a meta-analysis of RCTs contrasting the effects of raloxifene with those of a placebo, raloxifene typically led to a decreased risk of vertebral fractures in postmenopausal women (OR=0.6; CI 95%: 0.5-0.7).
The results of the MORE trial indicated that, following a raloxifene treatment period of four years, at 60mg per day, the cumulative relative risk of one or more vertebral fractures was 0.64 (IC 95%: 0.53 - 0.76), compared with treatment using a placebo.
Verus placebo, treatment with 60mg of raloxifene was also linked to a decrease of 65% to 78% in occurrences of invasive breast cancer and invasive breast cancer with positive estrogen receptor (both p <0.05).
The MORE and CORE studies reported a link between raloxifene and an elevated incidence (1.7 times) of thromboembolism (TE), versus treatment using a placebo (95% CI: 0.93-3.14; risk difference total of 0.9/1,000 women-years) [34]. In a meta-analysis of nine trials, raloxifene treatment was linked with an elevated incidence of deep venous thrombosis and pulmonary embolism (OR=1.5; CI 95%: 1.1-2.1 and OR=1.9; 95% CI: 1.0-3.5, respectively) [35]. The RUTH trial (‘Raloxifene Use for The Heart’), which studied 10,101 postmenopausal women with an average age of 68 and presenting with coronary heart disease, indicated a link between raloxifene and an elevated incidence of fatal stroke (HR=1.49; 95% CI: 1.00-2.24, a rise in the absolute risk of 0.7/1,000 women-years) as well as an elevated risk of thromboembolism (HR=1.44; 95% CI: 1.06-1.95, a rise in the absolute risk of 1.2/1,000 women-years) in comparison with the placebo results. No elevated risk of myocardial infarction or other coronary events was indicated in the RUTH trial. Nevertheless, in line with the observations regarding thromboembolism and pulmonary embolism, the outcomes of a recent review of a sub-cohort of the trial indicated that age had an impact on the occurrence of coronary events. For women of 60 years or under, the rate of occurrence of coronary events was distinctly reduced with raloxifene (50 cases), compared with the placebo group (84 cases; HR=0.59; 95% CI: 0.41 to 0.83, p=0.003). Raloxifene was also linked with an elevated occurrence of hot flushes, especially amongst women with recent menopause onset [36].
We can conclude that raloxifene provides an alternative option within osteoporosis therapies for specific patients. The drug’s profile relating to heart disease and breast cancer is sound but its links to an elevated risk of venous thrombosis should be taken into account in its use as a treatment.
Bazedoxifene is a third-generation SERM. Some key differences have been demonstrated between the generations regarding their impact on the uterus and on breast tissue in particular [37]. The drug was developed with raloxifene as a template and by replacing the benzothiophene core with an indole ring [38].
In a phase II trial of healthy postmenopausal women, oral doses of bazedoxifene 2.5, 5, 10, 20, 30, or 40mg per day were as a rule well-tolerated and did not aggravate the endometrium. In addition, bazedoxifene 30 and 40 mg resulted in a notably reduced increase in the thickness of the endometrium and distinctly lowered the occurrence of uterine bleeding versus results from the placebo. In a two-year phase III trial of postmenopausal women at risk of osteoporosis, bazedoxifene 10, 20, and 40mg were proven to prevent bone loss and decrease bone turnover and were linked with a positive endometrial, ovarian, and breast security profile [39, 40].
A phase III, multi-centre, double-blind, randomised, controlled trial was formulated with the sole purpose of assessing the effectiveness of bazedoxifene in fracture prevention. The trial looked at 7,492 healthy postmenopausal women presenting with osteoporosis both with or without prevalent vertebral fractures. The women were randomly assigned to 20 or 40mg per day of bazedoxifene, 60mg of raloxifene, or to a placebo plus 1200mg of calcium and 400IU of vitamin D. The primary outcome was the occurrence of new vertebral fractures following a three-year treatment period. Secondary indicators included clinical vertebral fractures, worsening of vertebral fractures, non-vertebral fractures, breast cancer incidence, and variations in height. Both bazedoxifene 20 and 40mg reduced the occurrence of vertebral fractures to a similar extent as raloxifene versus the placebo. The occurrence at 36 months of new vertebral fractures was 2.3%, 2.5%, 2.3%, and 4.1% in the bazedoxifene 20mg, bazedoxifene 40mg, raloxifene 60mg, and placebo cohorts, respectively, with a distinct lowering of the relative incidence for new vertebral fractures of 42%, 37%, and 42%, respectively, versus placebo. There was no overall impact on non-vertebral fractures, with incidence rates of 5.7% and 5.6% for the bazedoxifene 20 and 40mg cohorts, respectively, versus 5.9% for the raloxifene cohort and 6.3% for the placebo cohort. Nevertheless, in a later review of women with elevated fracture risk (poor femoral neck T-score and multiple vertebral fractures, n=1,772), bazedoxifene 20mg reduced the incidence of non-vertebral fracture by 50% and 44% reduction relative to the placebo (HR=0.50; 95% CI: 0.28–0.90; p=0.02) and raloxifene 60mg (HR=0.56; 95% CI: 0.31–1.01; p=0.05), respectively [41].
Miller et al. demonstrated that deep venous thromboembolism was uncommon with bazedoxifene (0% to 0.6% with varying dosage levels after two years) and similar to the placebo (0.3%). The rate of occurrence and the intensity of hot flushes were comparable with raloxifene, but slightly elevated versus placebo [40]. In the trial by Silverman et al., leg cramps (10.9% to 11.7% with varying dosage after three years) and deep venous thromboembolism (0.4% to 0.5% with varying dosage after three years) were decidedly more prevalent with bazedoxifene compared with the placebo (8.2% for leg cramps and 0.2% for deep venous thromboembolism), while fibrocystic breast disease was markedly less frequent. No distinction in risk levels between bazedoxifene and placebo was noted for myocardial infarction, strokes (ischemic or hemorraghic), or retinal vein thrombosis [40-43].
We can conclude that bazedoxifene appears to have improved selectivity in contrast with other SERMs. The impact of bazedoxifene on the skeleton is not dissimilar to raloxifene, and bazedoxifene may be employed in the same way as raloxifene. The usefulness of bazedoxifene possibly lies in its risk profile being distinct to that of raloxifene, particularly with regards to uterine safety, and bazedoxifene may therefore present another option for the prevention and treatment of osteoporosis.
Lasofoxifene is a powerful third-generation SERM. It has a distinct structure compared to first- and second-generation SERMs (raloxifene, tamoxifen and clomiphene or idoxifene). Lasofoxifene displays powerful estrogenic and anti-estrogenic activity in vitro and in vivo, targeting any areas with estrogens receptors, including bone, uterus, breast, blood vessels, and liver. Lasofoxifene has been analysed in postmenopausal women with regards to the prevention and treatment of osteoporosis. Security and tolerance levels of lasofoxifene is similar to that of raloxifene, however nonadherence rates as a result of adverse events are greater with lasofoxifene. Despite these indications, results demonstrate that lasofoxifene treatment may lead to greater endometrial thickness versus the placebo, despite there being no evidence of an elevated incidence of endometrial hyperplasia or cancer.
The PEARL study, a three-year pivotal fracture study, showed that lasofoxifene elevated lumbar spine and femoral neck BMD by approximately 3%. Furthermore, vertebral fractures saw a decrease of 42%, and non-vertebral fractures of 27%, with a decrease in markers of bone turnover. Nevertheless, lasofoxifene did not reduce the risk of hip fractures [43].
Bisphosphonates are a member of a class of antiresorptive agents whose antifracture action is well-documented through randomised controlled studies. There have been no studies to compare different bisphosphonates, a fact which has prevented the identification of a definite order of effectiveness for treatment.
Bisphosphonates lower fracture risk as a result of its inhibitory action of osteoclasts, which enables the osteoblasts to synthesize bone in the resorption spaces and some bone lacunae. This produces an augmentation in bone mass. However, the bisphosphonates also increase bone quality, by conserving the bone architecture, as demonstrated in studies which have analysed the biopsies of treated patients and control subjects.
Bisphosphonates comprise pyrophosphate analogs in which the central oxygen has been replaced by a carbon atom and two side chains (R1 and R2). Two phosphate chains are vital to enable the drug to bind to bone and to have an antiresorptive effect.
Etidronate was the original bisphosphonate used in osteoporosis therapy. It is no longer used in current practice. Its greatest asset is most likely its cost. It augments bone mass in the spine and femur and lowers the risk of vertebral fractures, however it has not demonstrated a reduction in the incidence of femoral fractures [44,45].
Clodronate has been deployed in postmenopausal osteoporosis therapy in oral and intravenous treatments. The trials indicate that it reduces the risk of bone loss in the vertebral spine in comparison to control subjects, and it presents similar results to estrogens after two years. In a six-year long study, it was also demonstrated to lower the incidence rate of vertebral fractures. McCloskey et al. carried out a three-year, double-blind, controlled study to observe the impact of oral clodronate (800mg per day) on fracture rates. In this study, clodronate was linked with a distinct improvement in the mean lumbar spine and hip BMD. Furthermore, it significantly lowered the risk of vertebral fracture (relative risk, 0,54; 95% CI, 0,37-0,80; p<0,0001). Despite these outcomes, subsequent to the introduction of powerful nitrogen bisphosphonates, the first-generation bisphosphonates have been reduced to a therapy of last resort [46].
Alendronate is one of the most commonly deployed bisphosphonates. It augments vertebral bone mass approximately 6-8% and 3-6% at the hip in postmenopausal osteoporotic women after a three-year treatment. It demonstrates a reduction in vertebral and non-vertebral fractures of around 50% in this time period. In male osteoporosis, it has demonstrated improvements in bone mass of 5% after two years of treatment.
Alendronate is given orally, in doses of 70mg/week, fasting with 200 ml of water. The patient is prohibited from consuming solids or liquids for 30 minutes after treatment and must remain standing for this time.
The decisive study of alendronate, the FIT (Fracture Intervention Trial), demonstrated that the incidence of clinical fracture was reduced for the alendronate cohort compared to the control cohort (139 (13.6%) versus 183 (18.2%); relative hazard=0.72 (0.58-0.90)). The corresponding risk of hip and wrist fracture for the alendronate cohort when compared to the placebo cohort were 0.49 (0.23-0.99) and 0.52 (0.31-0.87) [47]. Ensrud et al. provided an assessment of a subset of FIT subjects who were patients with an elevated risk of fracture. The outcomes of this analysis demonstrate a decisive 47% lowering of the risk of new vertebral fractures in the alendronate cohort when set against the control cohort. A number of other papers have been generated from the FIT study, addressing multiple symptomatic fractures, bone mineral density, biochemical markers of formation and resorption, fracture prevention in osteopenic women, impact of alendronate continuation versus discontinuation, and the impact on women who lost bone over the course of treatment [48-51].
We can conclude that alendronate is a well-tolerated, secure and efficacious treatment method for postmenopausal osteoporosis, male osteoporosis, and glucocorticoid induced osteoporosis (GIOP).
This treatment has been proven to improve bone mass in spine and hip and to considerably lower the incidence of fracture in postmenopausal women. Treatment of postmenopausal women with osteoporosis with risedronate over a three-year period has produced a reduction in the risk of vertebral fractures in roughly 50% and non-vertebral fractures in 39% of subjects. At the hip, the fracture reduction rate is between 40 and 60%. After a five-year period, the outcomes are comparable. The treatment has demonstrated its anti-fracture efficacy after a six-month course. In other trials it has been proven that this reduction in risk was still present following a seven-year period of treatment, and was accompanied by a positive security profile. One of the principal studies of risedronate [52] looked at 5,445 women aged 70 to 79 years with osteoporosis (T-score at the femoral neck greater than -4 SD below the mean or lower than -3 plus a non-skeletal risk factor for hip fracture, such as poor gait or a tendency to fall) and 3,886 women aged at least 80 years with a minimum of one non-skeletal risk factor for hip fracture or poor BMD at the femoral neck (T-score below -4 or below -3 plus a hip-axis length of 11.1cm or greater). The subjects were given a treatment at random of either oral risedronate (2.5 or 5.0mg per day) or a placebo, over a three-year period. The outcomes indicated that the risk of hip fracture among subjects given risedronate was 2.8%, versus 3.9% among those given the placebo (relative risk, 0.7; 95% CI, 0.6 to 0.9; p=0.02). In the cohort of women with osteoporosis (70 to 79 years old), the risk of hip fracture among subjects given risedronate was 1.9%, versus 3.2% among subjects given the placebo (relative risk, 0.6; 95% CI, 0.4 to 0.9; p=0.009). In the cohort of subjects chosen principally for non-skeletal risk factors (those at least 80 years old), the risk of hip fracture was 4.2% for subjects given risedronate and 5.1% for those given the placebo (p=0.35) [52].
To assess the impact on vertebral fracture risk, Reginster et al. carried out a randomised, double-blind, controlled trial to evaluate the effectiveness and security of risedronate for reducing the risk of vertebral fractures in postmenopausal women with established osteoporosis. The trial was carried out at 80 locations in Europe and Australia. In total, 1,226 postmenopausal women with two or more prevalent vertebral fractures were given risedronate 2.5mg or 5mg per day or a placebo. Whilst the trial was carried out over three years, the 2.5mg cohort was ended by protocol amendment after two years. Risedronate 5mg lowered the incidence of new vertebral fractures by 49% over three years in comparison with the placebo (p<0.001). A distinct decrease of 61% was witnessed over the initial year alone (p=0.001). The decreased incidence of fracture was comparable in both cohorts after two years. The incidences of non-vertebral fracture saw a decrease of 33% in relation to the placebo figures over three years (p=0.06). Risedronate produced a distinct elevation in BMD at the spine and hip within a six-month period. We can conclude that risedronate 5mg was an efficacious and well-tolerated treatment for severe postmenopausal osteoporosis, decreasing the risk of vertebral fractures and increasing bone density in women with chronic osteoporosis [53].
In trials lasting three years, ibandronate has been proven to decrease the risk of vertebral fractures (52%) and improve vertebral BMD (6.5%) whilst not having a substantial negative impact on bone histology. It has also shown to be very efficacious in reducing bone loss in GIOP (glucocorticoid induced osteoporosis). In women with severe osteoporosis T scores (<-3), it decreases the risk of non-vertebral fractures up to 69% [54].
Randomised clinical studies such as MOPS (Monthly Oral Pilot Study) or MOBILE (Monthly Oral Ibandronate in Ladies) have indicated that the ibandronate monthly dosage is just as efficacious and safe as the daily dosage. Amongst the general population of the pivotal trial (BONE, Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe), the likelihood of adverse incidents of the gastrointestinal tract in both the daily and the intermittent treatment cohorts was similar to the control cohort. Dyspepsia was the only adverse incident with a marginally greater rate in subjects undergoing therapy with ibandronate [55].
Zoledronic acid is a third-generation bisphosphonate. It is roughly as powerful as alendronate, risedronate and ibandronate, however the application of this drug intravenously prevents any negative impact and in fact augments the bioavailability, whilst also improving compliance to 100%.
The HORIZON trial (Health Outcomes and Reduced Incidence with Zoledonic Acid Once Yearly Pivotal Fracture Trial) was a global, multi-centre, double-blind, controlled study of postmenopausal women with osteoporosis, whose goal was to demonstrate the increase efficacy of intravenous zoledronic acid 5mg compared with a control. Subjects presented with densitometric osteoporosis or densitometric osteopenia with a minimum of 2 mild to moderate vertebral fractures [56]. Over 7,700 women were involved in the trial and were monitored over a three-year period; particular scrutiny was made of new fractures, bone remodeling biochemical markers and densitometric developments. On completion of the trial, subjects that had been treated with zoledronic acid presented a decrease in the vertebral fracture risk of 70%. The decrease was comparable for the first two years of the trial, varying from 60% to 71%. In addition, subjects given zoledronate presented a decrease of 41% in hip fracture incidence and 25% in non-vertebral fracture incidence. The outcomes of bone density and biochemical bone remodeling markers were also markedly improved for the cohort given zoledronic acid. Furthermore, bone mineral density was elevated to over 6% in the lumbar spine and total hip, and to over 5% in the femoral neck. The biochemical markers of bone remodeling, after the initial transfusion of zoledronic acid, decreased significantly as anticipated, and stayed stable throughout the remainder of the trial [57].
Many subjects experienced adverse effects over the course of the trial, with a greater occurrence of these in the zoledronate cohort. This variance was explained by post-infusion syndrome, which commonly manifested itself 24-48 hours after the zoledronic acid infusion and dissipated three days after infusion. The syndrome presented with mild fever, myalgias, flu-like symptoms, headache and/or arthralgias and was dissipated with analgesic, non-steroid anti-inflammatory drugs or acetaminophen. A few subjects presented with passing renal function deterioration 9 to 11 days post-infusion, however these instances were of no clinical transcendence [57].
Perhaps the most significant conclusion in relation to zoledronate therapy is the 28% decrease in mortality of any cause, which was demonstrated in a cohort of over 2,000 subjects with femur fracture [56].
We can conclude that zoledronate therapy is extremely efficacious in the reduction of vertebral, non-vertebral and hip fractures. It reduces mortality, independent of the cause, following a femur fracture.Moreover, it is a low-risk therapy that avoids the gastrointestinal adverse events and high nonadherence rates that are commonly encountered with other bisphosphonates, but it should be dispensed and regulated with great caution when treating individuals with severe renal function impairment.
This class of treatments is usually well-tolerated, provided that they are administered carefully and that patients adhere to the instructions for their use. Esophageal ulcerations been encountered in situations where these treatments are given orally and on a daily basis. They must not be given to patients with gastric or esophageal ulcerations, or to patients with pyrosis (heartburn) which requires treatment. They must not be administered to pregnant women, or to individuals with chronic renal impairment. The intravenous bisphosphonates normally give rise to acute phase reactions with fever, arthromyalgia and flu-like symptoms that commonly dissipate before the second dosage and which can be mitigated by giving acetaminophen or ibuprofen concurrently. Hypocalcaemia can present more frequently, so it is advisable to give calcium and vitamin D concurrently. The renal function has to be regulated both prior to and following treatments of intravenous bisphosphonates.
The avascular necrosis of the jaw, also called osteonecrosis of the jaw, is a condition which has concerned many practitioners since Marx identified it for the first time in 2003 and it ought to be outlined more completely in another chapter [58].
Research linking atypical fractures of the femur with longstanding treatments of bisphosphonates caused the American Society for Bone and Mineral Research (ASBMR) to launch an enquiry to consider the important queries raised by the conclusions of this research. The enquiry’s committee identified both major and minor features of incomplete and complete atypical femoral fractures and advised that all significant features, including their location in the subtrochanteric region and femoral shaft, transverse or short oblique orientation, little or no associated trauma, a medial spike when the fracture is complete, and lack of comminution, be discernible in order to designate a femoral fracture as atypical. Minor features include the fracture’s relationship with cortical thickening, a periosteal reaction of the lateral cortex, prodromal pain, bilaterality, delayed healing, co-morbid conditions, and concurrent drug usage, including bisphosphonates, other antiresorptive agents, glucocorticoids, and proton pump inhibitors. On the strength of published and unpublished information and the wide application of bisphosphonates, the occurrence of atypical femoral fractures linked with bisphosphonate use for osteoporosis seems to be decidedly uncommon, especially in relation to the extent to which vertebral, hip, and other fractures are in turn prevented. Moreover, a causal link between bisphosphonates and atypical fractures has not been demonstrated. Nevertheless, new investigations infer that the incidence rate increases with longer periods of therapy, and there is a feeling of unease that a lack of understanding and underreporting could be hiding the true extent of the issue.
A 2008 trial of 12,777 Swedish women aged 55 years or more with a fracture of the femur was made public recently. Radiographs of 1,234 of 1,271 women presenting a subtrochanteric or shaft fracture were analysed. Fifty-nine subjects with atypical fractures were isolated. The relative and absolute incidence of atypical fractures linked with bisphosphonate treatment was calculated using a national cohort analysis. The 59 subjects were also subject to a comparison with 263 control subjects who presented typical subtrochanteric or shaft fractures. The cohort analysis indicated an age-adjusted proportional risk of atypical fracture of 47.3. The rise in global risk was 5 instances per 10,000 patient-years. In total, 78% of the fractured patients and 10% of the controls had been given bisphosphonates (multivariable-adjusted odds ratio of 33.3). The incidence level was independent of coexisting ailments. Following cessation of treatment, the incidence level was reduced by 70% per year from the time of last use (odds ratio, 0.28; 95% CI, 0.21 to 0.38) [59].
Conditions that give rise to bone loss, like osteoporosis, are caused by the imbalance in the cycles of bone remodeling favouring bone resorption. The receptor activator of the nuclear factor kB (RANK), and its ligand (RANKL) are critical for the differentiation, activation and survival of osteoclasts and, as a result are the most simple intermediary in the regulating of bone remodeling (Burgess et al.1999). It has been proven that the signaling of the RANKL is inherent to the pathophysiology of many bone loss conditions, such as primary and many secondary forms of osteoporosis.
Denosumab is a fully human monoclonal IgG2 antibody to RANKL that imitates the effects of osteoprotegerine (OPG), endogenous inhibitor of RANKL that blocks bone resorption.
Comercial denosumab is sold as a sterile, uncolored solution administered via subcutaneous injection.
Data is accessible from more than 50 clinical studies in healthy adults and patients with osteoporosis, bone loss linked with hormone-ablation treatments, rheumatoid arthritis, advanced cancer (multiple myeloma and advanced malignancies that involve bone and giant cell tumor of the bone collected since June 2001).
In the Denosumab Fortifies Bone Density (DEFEND) trial, a phase III, randomised, controlled trial of 332 postmenopausal women with osteopenia sorted by the length of menopause (<5 years, >5 years), denosumab showed a distinctive rise in lumbar BMD (6.5%) at the two-year point, in relation to the control (-0.6%). It also raised BMD in other sites including total hip, distal third of the radius, and whole body (p>0.001) in the two cohorts. The rate of side effects was comparable between the control cohort and the denosumab cohort [60].
In a comparative clinical study, the DECIDE (Determining Efficacy: Comparison of Initiating Denosumab vs. Alendronate) trial of 1,189 postmenopausal women with low BMD (T-score: ≤-2 SD), subjects were randomly allocated 1:1 to two groups, one to be given subcutaneous denosumab (60mg per 6 months) plus an oral alendronate placebo weekly or oral alendronate weekly (70mg) plus a subcutaneous denosumab placebo injection every 6 months. Denosumab raised total hip BMD in relation to alendronate (3.5% versus 2.5%, p<0.00001). A more significant increase in BMD could be witnessed with denosumab than with alendronate in other locations, as in the trochanter (4.5% vs. 3.5%), distal radius (1.1% versus 0.6%), lumbar spine (5.3% versus 4.2%) and femoral neck (2.2% versus 1.6%); p<0.0003. The security profile was comparable for the two cohorts. No subject in the trial developed antibodies in reaction to denosumab [61].
Another phase III, multi-centre, double-blind trial, named STAND (Study of transitioning from Alendronate to Denosumab) was carried out to assess the impact of denosumab in subjects who were undergoing alendronate treatment. Five hundred and four postmenopausal women ≥ 55 years old with a BMD T-score of <-2.0 and >-4 SD, who were taking weekly oral alendronate for a minimum of six months, were randomly assigned to the treatment for 44±33 months. Alterations to BMD and bone biochemical markers were assessed. After a year, the cohort taking denosumab (and had been given alendronate before the trial) presented a markedly elevated total hip BMD in comparison with the cohort which continued to take alendronate (1.9% versus 1.05%; p<0.00012). Markedly elevated BMD readings with denosumab in comparison with alendronate were also noted after one year at the lumbar spine, femoral neck, and distal radius (all p<0.0125). The side effects and serious side effects were comparable in both cohorts [62].
Lastly, the principal phase III study, the FREEDOM (Fracture Reduction Evaluation of Denosumab in Osteoporosis every 6 Months) study, involved 7,868 postmenopausal women with osteoporosis and a BMD T-score between <-2.0 and >-4 SD and assessed the effectiveness in fracture reduction of denosumab. Subjects were given 60mg subcutaneous denosumab or placebo every six months for three years. Approximately 23% of the subjects had experienced a prior vertebral fracture. The trial’s retention rate of subjects was 83%. The decrease in relative risk of fracture was 68% (2.3% versus 7.2%; p<0.0001) for vertebral fractures, 20% (6.5% versus 8.0%) for non-vertebral fractures and 40% (0.7% versus 1.2%) for hip fractures. In comparison to patients in the control cohort, patients in the denosumab cohort saw a proportional elevation of 9.2% in bone mineral density at the lumbar spine and 6.0% at the total hip at three years. No distinctive dissimilarities were apparent between patients who were given denosumab and those who were given a placebo in the overall rate of side effects, serious side effects, or nonadherence to the trial as a result of side effects. No instances of osteonecrosis of the jaw were found in either cohort during this decisive study (Cummings et al. 2009). Lastly, the positive effects of denosumab therapy were generally discernible following the first treatment and remained so over the course of up to eight years of denosumab therapy in an open-ended extension trial [63].
We can conclude that denosumab provides an extremely efficacious substitute for osteoporosis therapy through the reduction of bone resorption and the elevation of bone mineral density via the inhibition of RANKL. A distinct benefit of denosumab is its route of administration and dosage. A subcutaneous injection every 6 months is comparatively free of discomfort and improves the therapy retention levels.
A series of observations were published indicating a low occurrence of fracture in subjects residing in locations with elevated fluoride levels. Fluoride was first employed in osteoporosis therapy in 1961. It was authorised for the prevention of osteoporosis in several European countried, but was never given authorisation by the American Federal Drug Administration (FDA) [64,65].
The outcomes of studies into the impact of fluoride on the reduction of fracture risk are ambiguous. Some trials have shown a reduction in the risk of vertebral fractures under monofluorophosphate, or sodium fluoride treatment, whereas other trials, giving patients the same preparations and dosage, did not. In addition, one meta-analysis extends these investigations and identifies an elevated fracture risk with increasing dosages after four years [66-68]. As a result, fluoride is not employed in the treatment of osteoporosis any longer.
Within the range of treatment options available, teriparatide or recombinant human PTH (1-34), has a significant role to play. It is a member of the group of anabolic bone-forming drugs rather than the anti-resorptive or catabolic group. It is a catalyst for fresh bone formation by accelerating bone turnover in favour of formation. Teriparatide therapy improves trabecular connectivity and cortical bone thickness [69] and augments the mechanical properties of bone causing a marked reduction in vertebral and non-vertebral fractures in postmenopausal women with osteoporosis, male osteoporosis and corticosteroid-induced osteoporosis [70]. For this reason its application is deemed to be suitable mostly for individuals at high risk of fracture and for those for whom other drugs have been unsuccessful [71].
The original indication for teriparatide first made public was the treatment of established osteoporosis in postmenopausal women. Amongst the varying trials which have been carried out on this treatment, the FPT (Fracture Prevention Trial) is the most significant. It assessed teriparatide at dosages of 20 or 40μg/day in controlled conditions in 1,637 postmenopausal women with vertebral fractures. Subjects taking teriparatide presented a marked decrease in the rate of fresh vertebral and non-vertebral fractures. They also experienced elevated lumbar and femoral neck bone density. Whilst the 40μg/day dose had a greater impact on BMD, the risk of fracture did not vary to any marked extent between the two dosage levels, while the higher dosage was less tolerated (11% nonretention due to adverse events with 40μg/day compared with 6% with 20 μg/day or with the placebo). The dosage of 20μg/day presented a decreased risk of vertebral fracture of 65% and a decreased risk of non-hip non-vertebral fracture risk reduction of 35%. This trial was originally supposed to run over a 36-month period, but it was terminated when subjects had undergone on average 21 months of treatment for safety reasons following osteosarcomas witnessed in rats during drug toxicity trials [72]. In other trials it transpired nevertheless that this effect presented only in juvenile rats given with elevated doses of PTH [73]. In addition, no instances of osteosarcomas have been noted in humans.
A subset of subjects were monitored for a maximum of 18 months following the termination of the therapy. This subset, which had been given teriparatide, demonstrated an enduring 40% decrease in vertebral fracture risk at 18 months versus the control sample. These outcomes indicate that the drug’s positive impact on the rate of non-vertebral fractures continues beyond the termination of treatment [74].
Despite bisphosphonates being the current benchmark for the treatment of osteoporosis, several studies exist that have assessed whether the combination of teriparatide and BP can produce a positive impact. The trials indicate that, if both treatments are given at the same time, bisphosphonates reduce rather than increase the anabolic action of teriparatide [75].
Combined teriparatide and denosumab, on the other hand, improves spine and hip BMD to a greater extent than either treatment does when administered in isolation. In the DATA-HRpQCT study, subjects underwent high-resolution peripheral QCT assessments at the distal tibia and radius (postmenopausal osteoporotic women randomly assigned to take teriparatide 20μg daily (n=31), denosumab 60mg every 6 months (n=33), or both (n=30) for 12 months). In the teriparatide cohort, the overall volumetric BMD (vBMD) did not vary at either anatomic location but was improved in both other cohorts at both locations. The elevated vBMD at the tibia showed an increase in the combination cohort (3.1±2.2%) compared with either the denosumab (2.2±1.9%) or teriparatide cohort (-0.3±1.9%) (p<0.02). Cortical vBMD was reduced by 1.6±1.9% at the tibia and by 0.9±2.8% at the radius in the teriparatide cohort whilst it was elevated in both other cohorts at both anatomic locations. Tibia cortical vBMD saw greater increases in the combination cohort (1.5±1.5%) than in the other two cohorts (p<0.04 for both comparisons). Cortical thickness was not affected in the teriparatide cohort, but was elevated in the other cohorts. Elevations in cortical thickness at the tibia was more marked in the combination cohort (5.4±3.9%) than the other cohorts (p<0.01 for both comparisons). In the teriparatide cohort, radial cortical porosity was raised by 20.9±37.6% and by 5.6±9.9% at the tibia but was not affected in the other two cohorts. Bone stiffness and failure load, as calculated through finite element analysis, was not affected in the teriparatide cohort but was elevated in the other two cohorts at both locations. These results suggest that the application of denosumab combined with teriparatide has a positive impact on HR-pQCT indices of bone quality to a greater extent than either treatment in isolation and may be of significant clinical benefit in the management of postmenopausal osteoporosis [76].
The EUROFORS study was a prospective, open-label, randomised study of 865 postmenopausal women with established osteoporosis and aimed to assess a variety of consecutive applications of teriparatide over a two-year period. Subjects were split into several subsets based on their former therapies. The outcomes of the BMD variations and biochemical markers of bone formation indicated that the application of teriparatide has a beneficial impact on bone mass and osteoblast function in postmenopausal women with established osteoporosis whatever the extent or type of former long-term exposure to antiresorptive treatments has been.
The length of the antiresorptive treatment and the length of pause in treatment between the former therapy and the teriparatide had no impact on BMD levels at any anatomic location. The skeletal reaction at the lumbar spine was comparable among former antiresorptive treatment cohorts at every point in time over the course of the trial, however subjects who had previously been given etidronate presented a greater increase, most likely a factor of its poorer anti-remodeling action. At six months, overall hip and femoral neck BMD showed a marked reduction in the former alendronate subset, and total hip BMD showed a marked reduction in the former risedronate subset. Overall hip and femoral neck BMD was statistically reduced from baseline in all other subsets at the six-month point. Nevertheless, this short-term reduction was contradicted over longer-term teriparatide therapy. All subsets demonstrated a numerically distinctive rise in BMD versus baseline after 18 and 24 months of therapy, and without variations between the cohorts at any point in the trial [77].
In a further non-randomised trial, 59 postmenopausal women with osteoporosis formerly given raloxifene or alendronate over an 18-36 month period, were treated with teriparatide over 18 months. Variations in BMD and bone-turnover markers were analysed. Subjects who had formerly been given alendronate saw a delayed rise in bone-turnover markers with results more than a third lower than those of subjects who had formerly been given raloxifene. Over the initial six-month period there were marked variations in the rise in BMD at the lumbar spine and hip. Subjects formerly given raloxifene saw more significant rises in BMD at the two sites. After 18 months of therapy marked variations continued in the lumbar spine, with greater improvement in subjects previously given raloxifene, however the variations in the hip were not as decisive. This proves that this application of teriparatide augments bone turnover in subjects formerly given raloxifene or alendronate, and that this improvement comes sooner and is more significant with the raloxifene pretreatment cohort [78].
Studies have also been published which demonstrate the effectiveness of teriparatide in the management of GIOP. In a randomised, double-blind study, 428 subjects both male and female from 22 to 89 years old, who had been given corticosteroids for a minimum of three months were randomly assigned to be treated with either alendronate 10mg/day or teriparatide 20μg/day over an 18 month period. After a year, the overall femur BMD was greater in the teriparatide cohort and on termination of the trial there were fewer vertebral fractures in the teriparatide cohort [79].
Teriparatide has also been employed as a treatment in men with osteoporosis. The trial analysed results from men with idiopathic or secondary osteoporosis being treated with teriparatide in comparison with a control group. The trial indicated elevated results, independent of gonadal status and other influential elements in the teriparatide cohort [80].
Overall, teriparatide (recombinant human PTH (1-34)) injections are well-tolerated. It disappears from the bloodstream in less than four hours following subcutaneous administration. Injections on a daily basis are required and a passing reddening at the injection site has been observed. Headache and nausea have been noted in under 10% of patients treated with a daily dose of 20µg. Mild, early, short-term hypercalcemia can transpire, but severe hypercalcemia is uncommon. Higher levels of urinary calcium (up 30µg per day) and serum uric acid concentrations (up 13%) are witnessed, however these do not seem to have clinical ramifications.
We can conclude that teriparatide is an appropriate and effective drug for the management of osteoporosis. It is efficacious in addressing a variety of clinical conditions, e.g. male osteoporosis or corticosteroid-induced osteoporosis.
Intact PTH (PTH 1-84) has been reported to have a beneficial impact on bone micro-architecture and to reduce incidence of fresh fractures as a result of its bone-forming mode of action [81].
PTH 1-84 is not procurable any more due to the withdrawal of its marketing licence at the behest of the regulating authority.
The possible clinical applications of strontium were revealed in approximately 1940, when strontium-89 was deployed as an analgesic treatment for bone metastases caused by prostate cancer [82,83].
In-vitro, strontium ranelate augments collagen and non-collagen protein synthesis through mature osteoblasts. The bone-forming action has been demonstrated by the higher levels of replication amongst pre-osteoblastic cells. This catalytic action on the duplication of pre-osteoblastic cells and the higher levels of collagen and non-collagen proteins have caused strontium ranelate to be regarded as a dual effect bone agent, because it does not simply reduce resorption [84]. The principal tool that can determine bone resorption at a molecular level is the RANK/RNAKL/OPG system outlined above. Solutions of 0.1mM to 2nM of strontium ranelate reduce the capacity of human osteoblasts to cause osteoclast differentiation, by reducing expression of mRNA of RANK-L and boosting mRNA expression of OPG, as reported in the trials carried out by Brennan et al. in 2006 [85, 86].
Studies have shown that the chemical properties of strontium ranelate cause the, densitometric values of subjects given the compound to be greater than the true values. Complex mathematical formulas exist to cut out the statistical impact of this from the DMO value, however it is more straightforward and sufficiently accurate to assume instead that half of the DMO achieved in the first year of therapy with strontium ranelate is a result of elevations in BMD and the remainder is a result of the basis caused by the heavier strontium measured by the DXA [87].
Information from the SOTI (Spinal Osteoporosis Therapeutic Intervention) study and the TROPOS (Treatment of Peripheral Osteoporosis) study looked at 1,649 postmenopausal subjects (SOTI trial) and 5,091 subjects (TROPOS trial) [88,89]. The initial three-year outcomes demonstrated a decrease in vertebral fractures of 41% with a NNT of 9. Moreover, an improvement in BMD of 12.7% was recorded. The decrease in vertebral fractures at the end of the four- and five-year periods was 33% and 24% respectively. In relation to non-vertebral fractures, the reduction in the relative incidence of fracture with strontium ranelate was 16% at the end of the three-year period and 15% at the end of the five-year period. A later assessment of these results in a subset of 1,977 subjects with high fracture risk (≥74 years old and a T-score of ≤-2.4) indicated a decrease in the incidence of vertebral fracture of 36% at the end of the three-year period and 43% at the end of the five-year period [87, 90].
Strontium ranelate was deployed in a widespread manner across Europe up to February 2014, when the European Medicines Agency (EMA) advised that the use of the drug be limited to cases which cannot use other treatments approved for osteoporosis, and that subjects with high risk for ischemic cardiac disorders should be excluded from this treatment option. This decision was grounded in a study carried out by the Pharmacovigilance Risk Assessment Committee (PRAC) that highlighted doubts about cardiovascular security which went beyond the risk, already known, of venous thromboembolism. On the basis of the PRAC analysis, an elevated incidence of serious cardiac disorders (including myocardial infarction) was pinpointed and steps were put forward to minimize the risk, specifically targeting the highlighted issue, in April 2013.
As set out in this review, there are several treatment options for osteoporosis. Unfortunately the choices are more restricted in daily clinical practice as treatments have been removed or their use restricted. Table 2 provides a summary of those treatments currently available to practitioners.
\n\t\t\t\t | \n\t\t
Current available osteoporosis therapies
Cathepsin K is expressed in the main in osteoclasts and a variety of other multinucleated cells including giant foreign body cells and Langhans cells. To a lesser extent it is present in macrophages, synovial fibroblasts, and fibroblasts at sites of wound repair or inflammation, chondrocytes, various epithelial cells of the human fetus, adult lung airway epithelium, thyroid epithelium, and potentially in low levels within smooth muscle cells. When the enzyme has been synthesised, it is separated into lysosomes and can be introduced into the extracellular environment. It is introduced particularly into the resorption lacuna below actively resorbing osteclasts where it is causes the degradation of the collagen type I dominated organic bone matrix. Thus, in a similar manner to pycnoidisostosis, removal of cathepsin K from osteoclasts prevents bone resorption. Inhibitors of cathepsin K are reported to have a less significant impact on osteoclast–osteoblast interaction, causing a lower inhibition of bone formation than available bisphosphonate antiresorptive drugs. Human cathepsin K inhibitors have been proven to stop bone loss in ovariectomized mice without reducing the anabolic effeciveness of parathyroid hormone (PTH) [91].
Whilst no CatK inhibitor is licensed for osteoporosis treatment or prevention at the present time, trials of three CatK inhibitors for the management of osteoporosis have been published: balicatib, relacatib, and odanacatib.
Balicatib is extremely selective for CatK in enzyme potency tests but has a reduced selectivity in living tissue. Clinical trials of balicatib have shown elevated BMD in postmenopausal women, but the drug was linked with cutaneous adverse effects. The first presentation of the efficacy of cathepsin K inhibitors on human bone density was witnessed with balicatib. This study, released by Adami et al. at an ASBMR meeting in 2009 (Denver, CO, USA), was a multi-centre, randomised, controlled, 12 month, dose-range identifying trial of 675 postmenopausal subjects with lumbar spine T-score less than 2.0. In the cohort treated with 50mg of balicatib daily, markers of bone resorption were reduced by over 55% with no reduction in markers of bone formation (osteocalcin, bone-specific alkaline phosphatase and N-terminal propeptide of type I collagen). The lumbar spine BMD was elevated 4.46%, that of the total hip was elevated 2.25%. Cutaneous reactions, including pruritus and morphea-like alterations, were observed in a low number of subjects. In a limited Japanese study, intact PTH levels were demonstrated to be elevated by 50% with balicatib treatment [92].
Relacatib is a powerful but nonselective inhibitor of cathepsins K, L, V, and S for which no clinical data in humans has been made public. The use of relacatib with ovariectomized and control monkeys caused an acute and rapid decrease in bone markers, and the impact of this lasted for a maximum of 48 hours, according to the dosage administered [93].
On the basis of the adverse effects, especially the cutaneous reactions, the production of all cathepsin K inhibitor drugs has been discontinued or put on hold, with the exception of odanacatib and, at present, ONO 5334
Odanacatib is a potent, selective inhibitor with an ability to inhibit cathepsin K in osteoclasts [91].
Two trials have been undertaken to assess the effectiveness and security of odanacatib, a phase I study to determine the dosage and a phase II study to assess the security and effectiveness. In the Phase I study a cohort of 49 women was used to assess a weekly dose. Doses of 5mg, 25mg, 50mg, and 100mg were used and 12 subjects were placed in the control cohort. A cohort of 30 women was created to enable the evaluation of the daily dosage. Doses of 0.5, 2.5, and 10mg were deployed, with six subjects placed in the control cohort. All treatments were given under fasting conditions. Odanacatib had an extended half-life of between 66 and 93 hours for all the treatments and dosages assessed. The effectiveness of both weekly and daily dosages in altering the markers was assessed. The impact was dose-dependant but not in proportion to the dosage level. Decreases in resorption markers were highest for weekly doses >50mg and daily doses ≥2.5mg. The greatest suppression was witnessed between days 3 and 5 with the weekly dose and this level remained elevated until the subsequent treatment [95].
The Phase II trial presented by Cusick et al. at the ASBMR meeting in 2009 (Denver, Co, USA), was a double-blind, randomised, controlled study lasting one year, with an expected extension period of two years. It looked at 399 postmenopausal women (postmenopausal (5yr) or bilateral oophorectomy) aged 45 to 85 years, presenting a T-score <-2 but not less than -3.5 in any one location. Subjects were assigned to five different cohorts with differing dosage levels: placebo, 3mg/week, 10mg/week, 25mg/week and 50mg/week. The variations in BMD at the lumbar spine were analysed and taken as the main outcome. In addition, variations in bone remodeling, variations in BMD in other locations and side effects were assessed in turn. The data indicated a elevation in BMD in all locations, which was related to the dose level. The more significant improvement was achieved with the highest dose. Weekly treatments of 50mg of odanacatib augmented bone mass by 5.7% in the lumbar spine, 4.1% in the total hip, 4.7% in the femoral neck, 5.2% in the trochanter and 2.9% in the distal third of the radius at the two-year point. Resorption markers dropped relative to the dose from the start of the therapy and stayed lower over the initial six-month period, at which point they increased to a similar level as those in the control group.
The data from the extension period of the phase II study to the three-year point (reported by Eisman et al. at the ASBMR meeting 2009 in Denver), looked at 169 women randomly assigned to weekly doses of odanacatib 50mg or a placebo. In the odanacatib cohort, BMD continued to rise (lumbar spine 7.5%, total hip 5.5%, femoral neck 5.5% and trochanter 7.4%). The urine NTX resorption marker was reduced by 50% versus the placebo, while the BSAP (bone specific alkaline phosphatase) formation marker remained unchanged. At the three-year point, formation markers had not only not decreased, but had in fact risen by 18% above baseline values.
ONO5334 is a new cathepsin K inhibitor. An initial trial has been carried out to assess its effectiveness and security in the treatment of postmenopausal osteoporosis. This was a year-long, randomised, double-blind, placebo and active-controlled parallel-group trial carried out across 13 locations in six European states. The study looked at 285 postmenopausal women from 55 to 75 years old with osteoporosis. Patients were randomly assigned to one of five dosage groups: placebo; 50mg twice daily, 100mg once daily, or 300mg once daily of ONO-5334; or alendronate 70mg once a week. After 12 months of monitoring all ONO-5334 doses and alendronate demonstrated a marked elevation of BMD at the lumbar spine, total hip (except the 100mg/day cohort), and femoral neck. There was little or no evidence that ONO-5334 suppressed bone-formation markers versus the alendronate, however the suppressive action on bone-resorption markers were comparable. There were no security issues of any clinic consequence. With a marked elevation in BMD, ONO-5334 also heralds a new mechanism in the treatment of osteoporosis. This new agent increases the range of treatments available both in the class of cathepsin K inhibitors as the second apparently available agent, and also across the full range of osteoporosis treatment [94].
We can conclude that Cathepsine K inhibitors are a new class of treatment that adds to the range of therapies available for the treatment and prevention of fractures, the most hazardous consequence of osteoporosis. Being able treat this condition at a variety of points along the resorption pathway is an asset and it provides clinicians with the opportunity to reduce the risk of fractures more effectively than before.
Sclerostin is a protein encoded by the SOST gene [96, 97]. It is identified as an important inhibitor of osteoblast-mediated bone formation [98, 99]. Loss-of-function mutations in this gene are linked with sclerosteosis, which results in progressive bone overgrowth and elevated bone mass and BMD.
A similar condition is van Buchem disease, a less severe form of sclerostosis resulting from by a deletion downstream of this gene, and leading to reduced sclerostin expression. SOST gene knockout mice no longer produce sclerostin and have an elevated bone mass, which demonstrates the impact this protein has on bone mass and BMD levels. In addition to elevated bone mass and BMD levels resulting from sclerostin deficiency, it is notable that no fractures have been reported in patients with either sclerosteosis or van Buchem disease [99, 100].
Sclerostin binds to low-density lipoprotein receptor-related protein (LRP) 5/6 and intercepts Wnt-signaling, governing bone formation in a negative manner and preventing osteoblast differentiation, proliferation, and activity [101].
At the present there are three separate humanized sclerostin antibodies under investigation: romosozumab (AMGEN & UCB), blozosumab (Eli Lilly) and BPS804 (Novartis). Romosozumab is a high affinity immunoglobulin G2 (IgG2) monoclonal antibody. It is produced through the humanisation of a mouse sclerostin monoclonal antibody that neutralizes sclerostin. The first-in-human single-dose trial in healthy men and postmenopausal women was carried out to assess pharmacokinetics, pharmacodynamics, tolerance and security of romosozumab doses of 0.1, 0.3, 1, 3, 5 or 10mg/kg delivered sub-cutaneously and 1 or 10mg/kg delivered intravenously. Seventy-two subjects in total took part in the trial and were subsequently monitored for a maximum of 85 days. The pharmacokinetics of this agent were not relative to the dosage levels. Dose-related rises in bone formation markers and falls in bone resorption markers were noted. A small proportion of subjects presented anti-investigational product bodies however the majority of these were non-neutralizing antibodies. The data indicated that the agent was well-tolerated [102].
In a phase II, multi-centre, multi-dose, controlled, parallel groups clinical study, 419 postmenopausal women with poor BMD were randomly assigned to the treatment to assess the effectiveness of romosozumab versus alendronate, teriparatide and a placebo, over a one year course of therapy. The main outcome was BMD change. All the dosage levels of romosozumab causes a marked elevation in the BMD at the lumbar spine, femoral neck and total hip together with a short-term rise in the bone formation markers and a durable fall in the bone resorption markers [103]. Data from the phase III studies is to be published soon.
A randomised, double-blind, controlled phase II clinical study of blosozumab in postmenopausal women with poor BMD was recently made available. Subjects were given subcutaneously administered blosozumab 180mg Q4W, 180mg Q2W, 270mg Q2W or equivalent placebo over a period of one year. In total, 120 women took part. Dosage levels across the range of blosozumab augmented lumbar spine and total hip BMD. Bone formation markers rose rapidly during the therapy while bone resorption markers fell at an early point in the therapy and continued at low level through to the end of the trial [104].
A comparable study was carried out using BPS804 with a similar cohort, however no data is yet published from this trial.
We can conclude that anti-sclerostin antibodies may be the most efficacious agent in the treatment of osteoporosis and bone defect related conditions.
Over the last decade, new drugs have come forward as potential pharmacological treatments for osteoporosis. More recent options are part of new classes of agent which present optimised modes of action, allowing practioners to replace patients’ lost bone mass more quickly and efficaciously than with older treatments. Nonetheless, it is important to be aware that all drugs have their appropriate uses and also a wide range of side effects, factors which must be considered in any clinical decision-making process. Furthermore, it is vital that practitioners ensure that, as required by the majority of therapies, treatments for osteoporosis are administered alongside adjustments in a patient’s lifestyle and/or calcium and vitamin D supplementation. New treatments are now coming into use that are likely to enable practitioners to opt for shorter courses of therapy which result in better outcomes for patients.
The purpose of this study is to understand how Islam assesses creativity—specifically, to determine if an Islamic framework for assessing creativity can be identified. Islam does not provide a framework for assessing creativity, yet Islamic scholars assess creativity. The research question is: How is creativity assessed in Islam?
Prior to this study, there has been research conducted examining how creativity is effective in Islam [1]. However, that research did not focus on how Islam assesses creativity. It does not look at the required support of ulemas and the application of Islamic reasoning to determine effective and approved creativity in Islam. It also does not examine how creativity is rejected in Islam. The need for this study was due to gaps in other studies. This study will explore the stage of Islamic creative thinking, legal reasoning, and deductive reasoning in Islam, creating a creative framework that has not yet been established.
This study was conducted with the assistance of seven informants from seven leading Islamic traditions based in the UK. Each informant provided unique insight into their understanding and interpretations of Islamic scriptures and texts in relation to creativity and its assessment. This study demonstrates how perceptions and practices of differing Islamic traditions compare with each other.1
The uniqueness of creativity research in Islam is the explorative nature of this research lends itself to qualitative study such as religious ethnography and discourse analysis will form two key approaches [2]. Religious ethnography will assist in eliciting responses from each informant, and discourse analysis will be used to identify different perspectives [3].
The objectives are:
To understand if Islam promotes or limits creativity in its followers;
To understand if it is the differing interpretation of the sacred scriptures and laws in Islam that is restricting creativity among its followers;
To understand the application of Quran to the assessment of creativity;
To understand the application of Ahadith to the assessment of creativity;
To understand the application of Sunnah to the assessment of creativity;
To understand the application of Shariah Law to the assessment of creativity;
To produce a framework for measuring creativity in Islam; and
To establish the extent to which the framework will assist differing interpretations and Islamic traditions in producing new creative ideas in Islam.
Islam came at a time when there was prevalent ignorance in pre-Islamic Arabia. The Quran guided Muslims to be creative and to use their creativity for the benefit of humanity and in accordance with Sharia law and Islamic principles [4]. The Quran promoted creativity by providing examples of creativity to inspire and make Muslims understand in a greater depth. The Quran created a system that allowed Muslims to become focused with helping people and societies by being inventors of new theories and ideas. Science, math, biology, languages, culture, geography, psychology, sociology, algorithms, and many other areas began to take shape, assisting and creating new building blocks that lead to the great Islamic civilisations that followed.
Allah is the Creator of the universe; therefore, a question sometimes arises about whether the phrase “to create” or the Arabic word “khalq” should be used to refer to human beings as creators. It is a consensus (ijma) among scholars that Allah is the Creator of all creation but it is sometimes debated that can Muslims or people be referred to as a creator? However, the Quran uses the word “khalq” when addressing and referring to the people; it states, “You only worship idols besides Allah and you create (khalq) a lie.” [5] This lends assists te premise that the Arabic word “khalq” can be used to refer to human invention and creativity as Allah has used it to highlight the lies created2 [6].
The Quran is seen as a creative miracle, as it holds accounts of the past and the future and cannot be duplicated by human beings. Allah, knowing this, provides three creative challenges to all of creation, including Muslims, to display creative intellect. In the first challenge, He states, “Say: ‘If all mankind and the jinn would come together to produce the like of this Quran, they could not produce it’s like even though they exerted all and their strength in aiding one another.’” [7] Knowing that they have failed in their creativity, He challenges them again to become creative by issuing a second challenge. He states, “Or do they say that he has invented it? Say (to them), ‘Bring ten invented chapters like it, and call (for help) on whomever you can besides God, if you are truthful.’” [8] When the humans and the jinn are unable to successfully provide ten chapters, Allah further challenges them, lowering the degree of the challenge to a single chapter. He states, “And if you all are in doubt about what I have revealed to My servant, bring a single chapter like it, and call your witnesses besides God if you are truthful” [9]. Allah in His three challenges challenged the whole of creation to create a chapter as He has done in the Quran. Allah’s challenge was also for those that spoke Arabic eloquently; they too were unable to successfully produce a chapter like that in the Quran. This is an example of Islam promoting creativity and asking people to become innovators, even asking the whole of creation to challenge Islam together. This challenge threatens the very fabric of Islamic existence but remains open to the whole mankind to participate in it.
Prophet Muhammad (pbuH) understood that all answers can be obtained from the Quran and that if any matters that required clarification then Muslims could go to Islamic scholars who are learned in the Quran, Ahadith, and Sunnah. The Prophet (pbuH) required Muslims to be learned and acquire knowledge throughout their lifetime. It is important to explain that many sects—including Salafi, Deobandi, and Wahabi—do not believe in Ahadith and Sunnah but rely solely on the Quran. They believe that any individual can translate the Quran. The Sunni, Sufi, Shia, and Berelvi sects believe the contrary. Such debates have led to segregation between the sects, causing difficulties for dialogue and rapport3 [10].
In relation to the Sunnah, the Quran states, “Your companion (Muhammad) is neither astray nor being misled. Nor does he speak of his own desire. It is (only) the revelation with which he is inspired” [11]. Therefore Muslims are required to believe that the Quran and Sunnah go hand in hand together as their sources of legislated law. The confusion between the sects’ relation to Ahadith and Sunnah is just a misunderstanding.
To understand the importance of knowledge in Islam from which creativity is derived, it is important to examine the first revelation to Prophet (pbuH) which was: “Read in the name of your Lord Who created. He created man from a clot. Read and your Lord is Most Honorable, Who taught (to write) with the pen. Taught man what he knew not” [12].
This is a very important revelation as the first revelation in Islam is asking the Prophet (pbuH) to read. For humans, reading is an essential tool to understanding which to gain knowledge leading to new ideas and creativity. Allah is then saying, “He created man from a clot;” “Who taught (to write) with the pen” and “Taught man what he knew not.” This is important, as Allah is telling the Prophet (pbuH) His creative nature. He is telling the Prophet (pbuH) that He taught man and provided knowledge and creativity to man as “pen” is a creative idea, another example of Islam promoting creativity.
The Prophet (pbuH) wanted Muslims to gain knowledge, and through knowledge Muslims would obtain a creative imagination (khayal), for the betterment of society. A Muslim imagination cannot become an automatic creation; therefore, creative ideas are within the confinement of Islam even at the very beginning. The Quran states, “Allah will raise in rank those of you who believe and those who have been given knowledge” [13]. The only source that can answer a question is the Prophet (pbuH), whose statements and practices have been recorded in the Ahadith and Sunnah. The Prophet (pbuH) said, “The seeking of knowledge is obligatory for every Muslim” [14]. The Prophet (pbuH) also said, “One who treads a path in search of knowledge has his path to Paradise made easy by God” [15, 16]. The Prophet (pbuH) is clearly indicating that knowledge is important for Muslims and is telling them that if they go in search of knowledge then their path to paradise will be made easy.
Muslims have been faced with great difficulties due to religious interpretations of the terms bid’ah (innovation), ijtihad (critical legal thinking), kufr (disbelief or denial), and shirk (avoid or neglect in the Oneness of Allah). Each will be examined in turn.
The word bid’ah has two meanings: the act of creating something new and the act of innovating. When bid’ah is used to counter creativity and innovation, the famous Ahadith is used to back up the argument opposing creativity: “Every bid’ah is misguidance and every path of misguidance goes to hell” [17]. To take this Hadith literally, it can be said that Prophet (pbuH) opposed all forms of bid’ah. However, the Prophet (pbuH) states, “If somebody innovates something which is not in harmony with the principles of our religion, that thing is rejected” [18]. Therefore, the Prophet (pbuH) permitted bid’ah and only opposed it when it was not in harmony with Islam. Furthermore, this Hadith confirms that introduction of new innovations or ideas are welcomed if they conform to Islam.
The Prophet (pbuH) further states: “He who introduced some good practice in Islam which was followed after him (by people) he would be assured of reward like one who followed it, without their rewards being diminished in any respect. And he who introduced some evil practice in Islam which had been followed subsequently (by others), he would be required to bear the burden like that of one who followed this (evil practice) without theirs being diminished in any respect” [19]. If a Muslim introduces a new practice or a good practice, then he will be rewarded for it. This Hadith is promoting creativity and innovation.
Allah states, “And whoever opposes the Messenger after guidance has become clear to him and follows other than the way of the believers. We will give him what he has taken and drive him into Hell, and evil it is as a destination” [20]. Allah is giving a warning that if any believer separates from the Prophet (pbuH) guidance, which includes the Prophet (pbuH)‘s guidance on bid’ah, then his abode will be hell4 [21].
The Prophet (pbuH) states, “The best speech is that which is embodied in the Book of Allah, the Al Quran; and the best guidance is the guidance given by me, Mohamed. The most evil affairs are the innovations (bid’ah), and every innovation (bid’ah) is an error” [22, 23, 24, 25, 26]. The reference to bid’ah here is relating to the creation of statements that oppose what has already been clarified in the Quran and explained by the Prophet (pbuH). It is therefore permissible to innovate that which benefits the religion and that which complies with Sharia law. This is where confusion stems between Muslims5 [19].
Ijtihad is a wide topic; for the purpose of this study, it will only relate to innovation (bid’ah). The term ijtihad is derived from the word “juhd,” which means to “endeavour” or “attempt” to achieve zann (presumption) regarding hukm (law) of Sharia law [27]. Ijtihad is used by Ulema when Muslims presume that an argument (dalil) is based on Sharia law or if they believe it may not be. Islam does not allow the reliance on presumption or conjecture but rather requires reason and evidence, as the Quran states, “O you who have believed, avoid much [negative] assumption (zann)” [28]. It further states, “And most of them follow not except assumption. Indeed, assumption avails not against the truth at all. Indeed, Allah is Knowing of what they do” [29]. Therefore, hukm (laws) can only be validated if they are certain in their arguments and methods and can have the backing of Sharia law; otherwise, they are deemed not permissible.
Ijtihad is similar to another creative process of thinking; namely, qiyas [30]. This is a process of analogical reasoning whereby the Quran, the Sunnah, and Hadith may be used to solve or provide a creative solution to a new problem. Ijtihad or even qiyas may be used as arguments in favour of innovation and opposing the concepts behind bid’ah, but this would require an Islamic scholarly consensus (ijma).
The Arabic term “ijma” refers to a consensus between Muslims on a particular topic. Muslim scholars to uphold the validity of ijma cite the following Hadith from the Prophet (pbuH): “Allah will never allow my Ummah to unite upon misguidance and incorrect beliefs” [31].
Muslims have been faced with great difficulties due to religious interpretations of the terms bid’ah (innovation), ijtihad (critical legal thinking), kufr (disbelief or denial), and shirk (avoid or neglect in the Oneness of Allah) when addressing the topic of creativity or innovation. These interpretations prevent an open dialogue about creativity in the Islamic world. The importance of Quranic exegesis, Hadith, and jurisprudence (fiqh) are important when addressing Sharia law, but for any argument to be valid in Islam it must have the backing of and be compliant with Sharia law and Sunnah, or the interpretation has no validity.
Sharia law refers to sacred laws in Islam. Sharia law is a concept of rule of law that applies to the whole of the ummah (brotherhood of Islam), covering family disputes, neighbours, business, finance, war, the community, and many other areas. Muslims are to adhere to and are subject to the punishments of Sharia law should a violation of Sharia law be committed. Non-Muslims are not subject to Sharia law or punishments.
The primary objective of Sharia law is rahmah (mercy). We have already examined how Quran and Sunnah are intertwined with one another. Allah states, “And We have not sent you, [O Muhammad], except as a mercy to the worlds.” [32]. The Prophet (pbuH) states, “Those who are merciful will be shown mercy by the Most Merciful. Be merciful to those on the earth and the One above the heavens will have mercy upon you” [33]. Allah and the Prophet (pbuH) have clearly defined the need for mercy and the Islamic scholars (ulemas) have agreed (ijma) that rahmah (mercy) is the objective of Sharia law.
To obtain an Islamic ruling in Sharia law, an examination takes place by the ulema against al-ʾaḥkām al-khamsa (the five statuses), which form part of fiqh (jurisprudence), when deciding a particular matter. They are as follows.
Recommended (mandub) ruling: a Muslim is not punished for not doing something recommended but is rewarded if he does do it;
Obligatory (wajib/fard) ruling: a Muslim is obligated to do something, does not do it, and is punished in the next life for not doing it;
Offensive/disliked (makruh) ruling: where a act is offensive/disliked and required not to be carried out;
Unlawful (haram) ruling: a Muslim does an act which is forbidden by Allah and therefore will be punished in this world and in the hereafter; and
Permissible (mubah) ruling: the Muslim is neither forbidden nor recommended to do something.. In Islamic jurisprudence this stage is used as an approval (ahkam) for matters that are not forbidden nor recommended in Islam, therefore it is a choice.
Sharia law plays an integral part in determining if issues or matters fall into the al-ʾaḥkām al-khamsa and if they are approved by Sunnah. To determine if creativity, innovation (bid’ah), or al-tafkir al-ibda’l (creative thinking) are compliant with Sharia law, a ruling would have to be provided in any of the above five statuses.
Religious ethnography will be used in this research to examine the responses [34] of seven informants belonging to seven separate traditions of opposing Islamic thinking and interpretations. It focuses on the religious believer, what he has been taught, the spiritual connection, his connection with the religious scriptures and texts and his ability to interpret them.
In-depth interviews are a method of collecting data from informants which will allow the identification of knowledge and processes of interpretation which are often invisible when they are embedded within a cohesive religious belief like Islam. The interviews provides the opportunity to find out the informants responses to questions making it easier to ask more complex questions and follow-up questions leading to a stronger interview and the ability to compare answers.
Currently, there are seventy-two different interpretations of the Quran therefore a strong possibility that there are seventy-two different definitions of Islamic creativity. Religious ethnography enables the researcher to make explicit the tacit and differing interpretations of Islamic creativity that would be difficult to elicit from reading scriptures and religious texts.
There will be face-to-face and one-to-one interaction between the researcher and the Informants which will be audio taped. The researcher will have the audio data transcribed and placed in a document clearly demonstrating each Informant’s response to each question. Using these complete texts, interpretative methodology derived from religious ethnography and discourse analysis will be undertaken to examine the language used or what the Informant or traditions accomplishes using such language.
Using complete texts from the recorded interviews and incorporating interpretative methodology derived from religious ethnography, discourse analysis will be used to examine the language used or what the Informant or faction accomplishes using this language [34]. This will allow the study to examine the responses of the informants allowing the researcher to apply the responses by identifying relationships within the data via a Grounded Theory approach to discover a new theory or framework to Islamic creativity. This is a unique study; therefore, the chance of this research or data replicating any prior theory is minimal, as no such theory exists [35].
The study is likely to employ additional ethnographic tools of inquiry such as observation and examination of relevant document to aid the interpretation of the Informant’s discourses; determine the informant’s nuances of the moment; the informants strategy in maintaining and managing involvement when interacting with the researcher, at the time of recording of the interviews; how meaning is constructed; the context (e.g. situational and background knowledge), and the researcher’s own interpretation and observations [2].
The study examines the Quran, Sunnah, Ahadith and Shariah Law to determine how Islam assesses creativity and how the informants interpret such scriptures and texts.
The sampling criteria used to identify and recruit the Informants is as follows:
at least 2 years’ experience as a qualified Islamic Scholar; and
understanding in Islamic Tafsir [36] (‘interpretation’ of the Quran); and
understanding in Ahadith (‘sayings of the Prophet pbuh’); and
understanding in Fiqh [37] (‘Islamic Jurisprudence and Islamic Law); and
provide sermons to the Muslim community and/or lead a congregation; and
understanding in Sunnah (‘practices of the Prophet pbuh’).
The Informants will belong to the following seven traditions:
Sunni;
Shia;
Wahabi;
Salafi;
Barelvi;
Sufi
Deobandi
Upon collecting the qualitative data (via interviews and observations), data analysis will be used to uncover a more interpretive analysis to examine the responses provided by the informants. The responses will then be categorised and indexed to highlight important features, patterns and similarities. The research will explore patterns and link similar responses to construct a theory that establishes an Islamic Creativity Framework.
A Grounded Theory will then be used to look for relationships within the data which may lead to establishing a creative framework [38].
The Informants are located in their respective Mosques and establishments in the UK, and their research interviews will be based around the following semi-structured questions:
In Islam, what is creativity?
Do different traditions have different perceptions on creativity in Islam?
Does Islam promote creativity?
How do you view creativity?
Does Islam limit creativity?
Does Islamic Law block the expansion of creativity in Islam due to its stringent rules on ethics?
Do you believe Islam should have a greater contribution to creativity?
What is the process of determining creativity in Islam in the absence of any guidelines that one can follow?
What would you say has been the biggest prevention in the rise of Islamic creativity?
Interviews will be conducted in Urdu, Punjabi, English or Arabic. Materials used to gather research will be a digital voice recorder along with two microphones for better voice quality.
Discourse analysis will examine how meaning is constructed and the power of Islamic interpretation that limits or expands Islamic creativity in society. Qualitative methodology will assist by categorising responses into patterns making it easier to organise and report results. The emphasis of a qualitative approach using ethnographic tools of inquiry is on context (e.g. situational and background knowledge context) and the researcher’s interpretation of the context observed. The approach aims to gain contextualised and naturalistic data for analysis.
This study examined how Islam assesses creativity. Seven interviews were carried out with ulemas from seven different sects: Imam Nasar (Sunni), Imam Alvi (Shia), Imam Chisti (Barelvi), Imam Rasab (Sufi), Imam Dawud (Salafi), Imam Younas (Wahabi), and Imam Huzayf (Deobandi). The themes the study examined are:
What creativity (bid’ah) is in Islam;
Differing perceptions of creativity in Islam;
Islam promoting creativity;
Islam limiting creativity;
Sharia law and creativity in Islam; and
Mechanisms needed to assess creativity in Islam.
Islam is a religion that was revealed to Prophet Muhammad (pbuH) and that incentivises the seeking of any knowledge for its believers.6 It is important to note that Islam views knowledge as a base of human intelligence and creativity as a branch of that intelligence. Therefore, when Islam refers to knowledge it is sometimes referring to creativity too. Islam provides rewards in the hereafter to Muslims for any knowledge gained in this world. Islam also incentivises the thought process of creativity, the journey and the destination of accumulating knowledge and creativity, and those rewards are rewarded separately at each stage. Islam makes it lucrative for Muslims to seek any knowledge, and as the Prophet (pbuH) states, “The best of people are those that bring most benefit to the rest of mankind”7 [40]. Islam uses itself as a mechanism, providing a platform to Muslims to bounce ideas by using the Quran in which Allah openly challenges mankind to do better than what He has done.8
Islam places great importance on creativity and innovation to create an ummatan wasatan, a “Middle Ummah” and a balanced society that avoids extravagance. Islam requires its followers to be moderate in belief (aqidah), in acts of worship (ibadah), in their understanding of Islamic law (Sharia law), and in morals and manners (akhlaq). Being moderate will allow Muslims to see both the liberal side of society and the extreme side of society, making it a fair religion that is able to view the whole of society. Therefore, its creativity will then assist the whole of society.
The interviews indicate that all informants understood what bid’ah meant in Islam. Imam Nasar (Sunni) explained that the definition of bid’ah means to create and that Islam is not against bid’ah. Imam Alvi (Shia) highlighted that even though bid’ah has controversy surrounding it, it does not mean it does not exist in Islam. He indicated that Muslims are not implementing bid’ah. Imam Chisti (Barelvi) interpreted the word bid’ah to come from the word badah, which means something new in Islam. Imam Rasab (Sufi), like Imam Chisti (Barelvi), explained that it is something new. Imam Dawud (Salafi) provided his interpretation of bid’ah, which is what was accepted at the time of the Prophet (pbuH). He explained that there is good bid’ah and bad bid’ah. Imam Younas (Wahabi) explained that it is something new to Islam and Imam Huzayf (Deobandi) described bid’ah as something not at the time of the Prophet (pbuH). The responses of Imam Dawud (Salafi) and Imam Huzayf (Deobandi) placed a negative outlook upon their understanding of bid’ah, as things have changed since the time of the Prophet (pbuH).
Imam Nasar (Sunni) explained that Islam does promote creativity, but only that which is not against Islam. He provided an example that the translation of the Quran was a new creative idea after the demise of the Prophet (pbuH). He stated that this benefits people and does not go against Islam. He also stated that some technologies that benefit people are allowed under Islam. Imam Alvi (Shia) agreed that Islam promotes creativity. He explained that Islam has asked Muslims to obtain knowledge even if they must go to China. He explained that the word “China” was never said by the Prophet (pbuH) but as knowledge was so important people just accepted that He (pbuH) may have said it. He described that currently people may feel that to be creative one must obtain Western knowledge or knowledge from people that follow a religion other than Islam. He also responded that Muslims have a right over knowledge and should go where knowledge is, even to other religions. Imam Chisti (Barelvi) believes that Islam allows all forms of creativity unless a form of creativity is wrong. He highlighted that if Islam views something as wrong, that thing will not be praised. Imam Rasab (Sufi) emphasised that Islam promoted creativity and it is divided into two categories: the good and bad bid’ah.9
On the question of different perceptions of bid’ah in Islam, Imam Nasar (Sunni) explained that some people have a complete ban on bid’ah. He further explained that in Sunni sect there are limitations on creativity definition but never a complete ban. He indicated that if Islam was against innovation then things that have been invented under Islam would not have been created. He suggested that Islam does not ban creativity but seeks its progression.
Imam Chisti (Barelvi) explained that there is one interpretation, but different schools of thought have taken control of this issue from different angles. Imam Chisti suggested that due to this control Muslims are not able to be creative. Imam Chisti in his response to those that attempt to control the explanations of bid’ah provided an example of Sahih Al Bukahri a collection of Ahadith; and asked if they were a good thing or a bad thing, as they came after the time of the Prophet (pbuH), indicating that bid’ah has benefits.
Imam Rasab (Sufi) said that there are different explanations, but the definition is the same. He provided his own examples of Arabic grammar, the book version of the Quran, the prayer timetable, and even the mobile phone. He said that these developments are a benefit and are accepted in Islam. The response of Imam Dawud (Salafi) was that there are different perceptions of bid’ah in Islam and that some practiced shirk. Imam Dawud (Salafi) emphasised that some sects fall outside the limits Islam has set. Imam Younas (Wahabi) and Imam Huzayf (Deobandi) both agreed with Imam Chisti (Barelvi) that there is one interpretation but different meanings.
There are many different interpretations of the Quran and AHadith relating to bid’ah by Scholars, but Allah states, “And whoever opposes the Messenger after guidance has become clear to him and follows other than the way of the believers. We will give him what he has taken and drive him into Hell, and evil it is as a destination” [20]. Allah is giving a warning that if any believer separates from the guidance of the Prophet (pbuH), which includes guidance on bid’ah, then his abode will be hell. Despite this clear warning, many Muslim ulemas—specifically, those in the Salafi, Deobandi, and Wahabi sects—take the literal meaning of the Hadith: “The most evil affairs are the innovations (bid’ah), and every innovation (bid’ah) is an error” [22, 23, 24, 25, 26]. These sects have reservations to the Ahadith due to the word “Ahadith” not appearing in the Quran. Their position then becomes contradictory, as they rely upon a Hadith despite having reservations to their authenticity as a source of guidance. However, Sunni, Shia, Sufi, and Barelvi are more open to the idea of relying on the Ahadith; and despite the word not appearing in the Quran, they believe that the Ahadith are the guidance from the Prophet (pbuH) and that that is what Allah refers to when He states: “And whoever opposes the Messenger after guidance has become clear.”
Imam Nasar (Sunni) believes that there are limitations on creativity in Islam. Muslims must comply with the rule or obligations of Islam, and creativity should not contradict Islamic principles or else it will be rejected. Imam Alvi (Shia) stated that Islam has not provided people with freedom but rather has asked them to remain within the Islamic guidelines. Imam Chisti (Barelvi) explained that if there is no Quranic injunction against it or any injunction against it, or if there is no Hadith against it, then Islam will promote that creativity. However, he explained that if there is solid proof or Quranic injunction or creativity goes against the Hadith then Islam will reject that creative idea.
Imam Rasab (Sufi) explained that if Sunnah and Quran are complied with then it is good bid’ah and Islam will not restrict it. Imam Dawud (Salafi) explained that Islam rejects bid’ah in its entirety. He explained that Prophet (pbuH) stated that if it is not of the way of the Prophet (pbuH), then it is rejected. Imam Younas (Wahabi) explained that there is a complete ban on bid’ah and that it has no place in Islam. He stated that Islam is complete and there is no room for new innovations to be brought about within Islam. Imam Huzayf (Deobandi) stated that Islam does limit creativity, but as there is good bid’ah and bad bid’ah it must fall into the statuses set out in Sharia law such as permitted, obligatory, recommended, unlawful, and offensive/disliked.
Bid’ah only has legal standing if it complies with Sharia law and the Sunnah of the Prophet (pbuH). Bid’ah is being used as a tool to prevent free thinking of ideas. This affects and the ijtihad process of the Muslims due to the substantial opposition to those that commit good bid’ah.
In response to those that oppose good bid’ah the following Hadith states, “He who introduced some good practice in Islam which was followed after him (by people) he would be assured of reward like one who followed it, without their rewards being diminished in any respect. And he who introduced some evil practice in Islam which had been followed subsequently (by others), he would be required to bear the burden like that of one who followed this (evil practice) without theirs being diminished in any respect” [19]. Sects such as Deobandi, Salafi, and Wahabi provide limitations that go far beyond the limitations required by Islam, preventing their followers from being creative by propagating the understanding that innovation is wrong. Sunni, Shia, Barelvi, and Sufi are utilising this Hadith to spread and promote creativity in Islam.
The difficulties due to religious interpretations or applications of bid’ah, qiyas, ijtihad, kufr, and shirk when addressing the topic of creativity or innovation are based on peer pressure, ignorance, and lack of knowledge in Islamic teachings. This leads to a schism, preventing an ijma to finally put these matters to rest. In the absence of an ijma, however, Muslims need only look at the inventions and creative thoughts of Muslims that have had a positive impact on Western civilization to reach the conclusion that Islam does not prevent or limit creativity [3].
Imam Nasar (Sunni) disagreed that Sharia law blocks creativity on the basis of ethics. He stated that if a Muslim follow the rules of Islam and Islam will not stop you. He explained that there are certain rules that permit people to do certain things and which are not against Islam. Imam Alvi (Shia) stated that Islam has rules that must be followed, and if creativity benefits people then Sharia law will not block it. Imam Chisti (Barelvi) explained that Islam does not block bid’ah and that if the bid’ah is beneficial to Muslims then Sharia law will not inhibit it. Sharia law will only block the expansion of bid’ah if it seems that the bid’ah is taking people away from the right path. Imam Rasab (Sufi) explained that Sharia law does not block bid’ah if it agrees with the Quran and the Sunnah and if it is a good thing.
There are guidelines that need to follow Sharia law. Imam Dawud (Salafi) explained that everything in worldly life is permissible unless we have sacred text prohibiting it. Imam Younas (Wahabi) proposed that a mufti be approached to seek an answer to this question. Imam Huzayf (Deobandi) said Sharia law does not block bid’ah and explained the need to look at the categories of Sharia law to seek compliance with it. These interpretations, however, prevent an open dialogue about creativity in the Islamic world. The importance of Quranic exegesis, Ahadith, and jurisprudence (fiqh) are important to when addressing Sharia law, but for any argument to be valid in Islam it must have the backing of, and be in compliant with, Sharia law and the Sunnah, or else the interpretation has no validity.
An Islamic ruling under Sharia law against al-ʾaḥkām al-khamsa, which forms part of fiqh when deciding bid’ah, declares that Islam does not prevent innovation unless it attempts to change the religious ideology or religious framework that covers the principles of Islam, as then that would be unlawful. The al-ʾaḥkām al-khamsa under Sharia law are: the obligatory, recommended, unlawful, offensive/disliked, and permissible. Out of the these only the “unlawful” status prevents certain bid’ah against the Islamic principles from taking place. As a result, Muslims can validate their creative ideas and innovations from the four remaining statuses in Islam. Sharia law propagates al-tafkir al-ibda’l (creative thinking) by making it a law that all Muslims to be creative thinkers.
All informants believed that the guidelines to follow when addressing creativity in Islam must include either all or some of the following stages: the intention (of the creator), the Quran, the Sunnah, the Hadith, Sharia law, and the ulema. This study provides an Islamic Creativity Framework with reliance on the Quran, the Hadith, and the Sunnah, which embed authority in Islam and provides clear guidance and direction to Muslims to be creative. Abd-Allah, in his study Innovation and Creativity in Islam, does not provide a methodology to assess creativity in Islam but provides one to promote creativity. He also uses the methodology of ijtihad to further the promotion of creativity in Islam but does not provide a connection or a process linking ijtihad to the Quran, Sunnah, the Ahadith, and qiyas [43].
Al-Karasneh and Jubran then rely upon ijtihad (and Sharia law as a secondary source) as a good methodology to reach creative ideas and new solutions. They then rely upon Quranic verses [44]. The difficulty with their research is that some verses of the Quran cannot be taken in their literal form. The Quran requires an interpretation which is found within the Ahadith and Sunnah and explained by ulemas. Al-Karasneh and Jubran have not done this. They have attempted to translate the Quran without any authority and as a result have not actually explained anything, as there is no interpretation to back up the verses of the Quran that they have cited. This study has cited the Quranic verses and backed them up with Sunnah and the Ahadith.
Having examined the responses from the informants, it is evident that for any new creative product to be accepted in Islam it must go to the ulema, who will decide if the creative product complies with the Quran and Sunnah. If the creative product is not compliant with the Quran and Sunnah, it will be rejected. If the creative product is compliant with the Quran and Sunnah it will pass this stage and then go to the five statuses of Sharia law. If a judgement is passed that the creative product is unlawful, then the creative product will be rejected by the ulema. However, if a judgement is passed that the creative product is permissible, lawful, obligatory, or offensive/disliked but is acceptable, then the creative product will be accepted.
If the creative product is something new that does not have a reference in the Quran or Sunnah, then the matter will enter qiyas. In this process of deductive analysis, if it is decided that the creative product is beneficial then it will proceed to the five statuses of Sharia law, as explained above. If the qiyas process is not accepted, it will be passed on to the elite ulema, who will apply ijtihad to determine its suitability in Islam. Once the ijtihad process is carried out and the judgement is passed that ijtihad supports the creative product, then it will pass to the five stages of Sharia law. If the judgement is that it is not supported by ijtihad, it will be rejected. The diagram below sets out this process (Figure 1).
The Islamic creativity framework.
When bid’ah is used to counter creativity and innovation the famous Hadith is used to back up the argument opposing creativity: “Every bid’ah is misguidance and every path of misguidance goes to hell” [17]. To take this Hadith literally, it can be said that Prophet (pbuH) opposed all forms of bid’ah. Before examining this Hadith with the assistance of Sharia law, it is important to first show examples of independent acts of bid’ah using personal ijtihad in the presence of the Prophet (pbuH), who did not object to them.
In the Ahadith, it is stated that the “Prophet (pbuH) said to Bilal, “Bilal, tell me which of your acts in Islam you are most hopeful about, for I have heard the footfall of your sandals in paradise’, and he replied, “I have done nothing I am more hopeful about than the fact that I do not perform ablution at any time of the night or day without praying with that ablution whatever has been destined for me to pray.”10 As the Prophet (pbuH) did not object to Bilal using personal ijtihad and creating a new act, it is regarded as permissible that a Muslim can reach a new act of innovation and rely upon personal ijtihad. The Sunni and Shia view this as an argument in favour of bid’ah, whereas Wahabi, Salafi, and Deobandi view this as being part of prayer and not bid’ah.11
The definition of bid’ah has been misunderstood by Muslims. The word bid’ah has two: meanings “to create something new” and “the act of innovating.” It can also be categorised into two groups: good bid’ah and bad bid’ah. The Prophet (pbuH) stated that “Every bid’ah is misguidance and every path of misguidance goes to hell” [17]. To take this Hadith literally as sects such as Deobandi, Salafis and Wahabi do, it can be said that the Prophet (pbuH) opposed all forms of bid’ah.12 The Sunni, Shia, Barelvi, and Shia sects all accept that creativity is acceptable in Islam and that this AHadith cannot be taken literally as Islam has had substantial advancement in the world. There are teachings among some sects namely Deobandi, Salafi and Wahabi that all bid’ah is bad and even the compiling of the Quran into a book would have some sects having reservations regarding that, considering the above AHadith.
The Prophet (pbuH) states, “If somebody innovates something which is not in harmony with the principles of our religion, that thing is rejected” [18]. The Prophet (pbuH) also states, “If a question relates to your worldly matters you would know better about it, but if it relates to your religion then to me it belongs” [47]. The Prophet (pbuH) has confirmed that Muslims know better when it comes to their worldly affairs. However, the Prophet (pbuH) only opposed creativity if it appeared to damage, change or not be in harmony with Islamic principles. It can be taken from the above Hadith that if a creative idea or product does not intend to do that then Islam will accept it and praise it.
The Quran, Ahadith, Sunnah and Sharia law are the mechanisms needed to assess creativity in Islam, and these all are authorities that Muslims follow. Islam does not seek to reject a creative product or idea even if the Quran or Sunnah has no guidance relating to it but rather proceeds to the stages of qiyas and if needed ijtihad, to determine the benefit of a creative product or idea before it is deemed accepted or rejected under Islam. This symbolises that Islam will exhaust all possible options before declaring a creative product or idea non-compliant within Islam.
The Islamic Creativity Framework has considered the responses, guidance, and input from seven informants belonging to seven sects. The importance of Islamic Creativity Framework is that all sects can accept that creativity is important in Islam, that reliance on sacred scriptures is significant, and that the seven sects can work together to reach a solution where all sects can agree on. Furthermore, the Islamic Creativity Framework provided in this study would under Islam be deemed as “good bid’ah” or “good creativity,” as it seeks to bring Muslims together and looks to advance knowledge and creativity among Muslims to overcome the misunderstandings that have existed between different Muslim sects for centuries.
IntechOpen books are available online by accessing all published content on a chapter level.
",metaTitle:"Access policy",metaDescription:"IntechOpen books are available online by accessing all published content on a chapter level",metaKeywords:null,canonicalURL:null,contentRaw:'[{"type":"htmlEditorComponent","content":"All IntechOpen published chapters are available OPEN ACCESS can be read without the requirement for registration of any kind, immediately upon publication, without any barrier.
\\n\\nThe HTML version, as well as the PDF version of publications dated before 2012 that are accessible through a reader, are available to readers with no restriction.
\\n\\nThe full content of chapters can be read, copied and printed from the link location of the chapter and these actions are not limited or restricted in any way.
\\n\\nRegistration is requested only to download the PDF of the chapter. There are no subscription fees and there is no charge to user groups.
\\n\\nIntechOpen chapters are distributed under CC BY 3.0 licences allowing users to “copy, use, distribute, transmit and display the work publicly and to make and distribute derivative works, in any digital medium for any responsible purpose, subject to proper attribution of authorship...” and there is no non-commercial restriction.
\\n\\nAuthors may post published works to any repository or website with no delay, and Authors and Editors of IntechOpen books have direct access to the PDF of the full book.
\\n\\nAll published content can be crawled for indexing. Full text and metadata may be accessed with instructions publicly posted.
\\n\\nAll IntechOpen books are indexed in CLOCKSS and preservation of access to published content is clearly indicated.
\\n\\nPolicy last updated: 2021-02-26
\\n"}]'},components:[{type:"htmlEditorComponent",content:"All IntechOpen published chapters are available OPEN ACCESS can be read without the requirement for registration of any kind, immediately upon publication, without any barrier.
\n\nThe HTML version, as well as the PDF version of publications dated before 2012 that are accessible through a reader, are available to readers with no restriction.
\n\nThe full content of chapters can be read, copied and printed from the link location of the chapter and these actions are not limited or restricted in any way.
\n\nRegistration is requested only to download the PDF of the chapter. There are no subscription fees and there is no charge to user groups.
\n\nIntechOpen chapters are distributed under CC BY 3.0 licences allowing users to “copy, use, distribute, transmit and display the work publicly and to make and distribute derivative works, in any digital medium for any responsible purpose, subject to proper attribution of authorship...” and there is no non-commercial restriction.
\n\nAuthors may post published works to any repository or website with no delay, and Authors and Editors of IntechOpen books have direct access to the PDF of the full book.
\n\nAll published content can be crawled for indexing. Full text and metadata may be accessed with instructions publicly posted.
\n\nAll IntechOpen books are indexed in CLOCKSS and preservation of access to published content is clearly indicated.
\n\nPolicy last updated: 2021-02-26
\n"}]},successStories:{items:[]},authorsAndEditors:{filterParams:{sort:"featured,name"},profiles:[{id:"6700",title:"Dr.",name:"Abbass A.",middleName:null,surname:"Hashim",slug:"abbass-a.-hashim",fullName:"Abbass A. Hashim",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/6700/images/1864_n.jpg",biography:"Currently I am carrying out research in several areas of interest, mainly covering work on chemical and bio-sensors, semiconductor thin film device fabrication and characterisation.\nAt the moment I have very strong interest in radiation environmental pollution and bacteriology treatment. The teams of researchers are working very hard to bring novel results in this field. I am also a member of the team in charge for the supervision of Ph.D. students in the fields of development of silicon based planar waveguide sensor devices, study of inelastic electron tunnelling in planar tunnelling nanostructures for sensing applications and development of organotellurium(IV) compounds for semiconductor applications. I am a specialist in data analysis techniques and nanosurface structure. I have served as the editor for many books, been a member of the editorial board in science journals, have published many papers and hold many patents.",institutionString:null,institution:{name:"Sheffield Hallam University",country:{name:"United Kingdom"}}},{id:"54525",title:"Prof.",name:"Abdul Latif",middleName:null,surname:"Ahmad",slug:"abdul-latif-ahmad",fullName:"Abdul Latif Ahmad",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"20567",title:"Prof.",name:"Ado",middleName:null,surname:"Jorio",slug:"ado-jorio",fullName:"Ado Jorio",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Universidade Federal de Minas Gerais",country:{name:"Brazil"}}},{id:"47940",title:"Dr.",name:"Alberto",middleName:null,surname:"Mantovani",slug:"alberto-mantovani",fullName:"Alberto Mantovani",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"12392",title:"Mr.",name:"Alex",middleName:null,surname:"Lazinica",slug:"alex-lazinica",fullName:"Alex Lazinica",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/12392/images/7282_n.png",biography:"Alex Lazinica is the founder and CEO of IntechOpen. After obtaining a Master's degree in Mechanical Engineering, he continued his PhD studies in Robotics at the Vienna University of Technology. Here he worked as a robotic researcher with the university's Intelligent Manufacturing Systems Group as well as a guest researcher at various European universities, including the Swiss Federal Institute of Technology Lausanne (EPFL). During this time he published more than 20 scientific papers, gave presentations, served as a reviewer for major robotic journals and conferences and most importantly he co-founded and built the International Journal of Advanced Robotic Systems- world's first Open Access journal in the field of robotics. Starting this journal was a pivotal point in his career, since it was a pathway to founding IntechOpen - Open Access publisher focused on addressing academic researchers needs. Alex is a personification of IntechOpen key values being trusted, open and entrepreneurial. Today his focus is on defining the growth and development strategy for the company.",institutionString:null,institution:{name:"TU Wien",country:{name:"Austria"}}},{id:"19816",title:"Prof.",name:"Alexander",middleName:null,surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/19816/images/1607_n.jpg",biography:"Alexander I. Kokorin: born: 1947, Moscow; DSc., PhD; Principal Research Fellow (Research Professor) of Department of Kinetics and Catalysis, N. Semenov Institute of Chemical Physics, Russian Academy of Sciences, Moscow.\r\nArea of research interests: physical chemistry of complex-organized molecular and nanosized systems, including polymer-metal complexes; the surface of doped oxide semiconductors. He is an expert in structural, absorptive, catalytic and photocatalytic properties, in structural organization and dynamic features of ionic liquids, in magnetic interactions between paramagnetic centers. The author or co-author of 3 books, over 200 articles and reviews in scientific journals and books. He is an actual member of the International EPR/ESR Society, European Society on Quantum Solar Energy Conversion, Moscow House of Scientists, of the Board of Moscow Physical Society.",institutionString:null,institution:{name:"Semenov Institute of Chemical Physics",country:{name:"Russia"}}},{id:"62389",title:"PhD.",name:"Ali Demir",middleName:null,surname:"Sezer",slug:"ali-demir-sezer",fullName:"Ali Demir Sezer",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/62389/images/3413_n.jpg",biography:"Dr. Ali Demir Sezer has a Ph.D. from Pharmaceutical Biotechnology at the Faculty of Pharmacy, University of Marmara (Turkey). He is the member of many Pharmaceutical Associations and acts as a reviewer of scientific journals and European projects under different research areas such as: drug delivery systems, nanotechnology and pharmaceutical biotechnology. Dr. Sezer is the author of many scientific publications in peer-reviewed journals and poster communications. Focus of his research activity is drug delivery, physico-chemical characterization and biological evaluation of biopolymers micro and nanoparticles as modified drug delivery system, and colloidal drug carriers (liposomes, nanoparticles etc.).",institutionString:null,institution:{name:"Marmara University",country:{name:"Turkey"}}},{id:"61051",title:"Prof.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"100762",title:"Prof.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"St David's Medical Center",country:{name:"United States of America"}}},{id:"107416",title:"Dr.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Texas Cardiac Arrhythmia",country:{name:"United States of America"}}},{id:"64434",title:"Dr.",name:"Angkoon",middleName:null,surname:"Phinyomark",slug:"angkoon-phinyomark",fullName:"Angkoon Phinyomark",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/64434/images/2619_n.jpg",biography:"My name is Angkoon Phinyomark. I received a B.Eng. degree in Computer Engineering with First Class Honors in 2008 from Prince of Songkla University, Songkhla, Thailand, where I received a Ph.D. degree in Electrical Engineering. My research interests are primarily in the area of biomedical signal processing and classification notably EMG (electromyography signal), EOG (electrooculography signal), and EEG (electroencephalography signal), image analysis notably breast cancer analysis and optical coherence tomography, and rehabilitation engineering. I became a student member of IEEE in 2008. During October 2011-March 2012, I had worked at School of Computer Science and Electronic Engineering, University of Essex, Colchester, Essex, United Kingdom. In addition, during a B.Eng. I had been a visiting research student at Faculty of Computer Science, University of Murcia, Murcia, Spain for three months.\n\nI have published over 40 papers during 5 years in refereed journals, books, and conference proceedings in the areas of electro-physiological signals processing and classification, notably EMG and EOG signals, fractal analysis, wavelet analysis, texture analysis, feature extraction and machine learning algorithms, and assistive and rehabilitative devices. I have several computer programming language certificates, i.e. Sun Certified Programmer for the Java 2 Platform 1.4 (SCJP), Microsoft Certified Professional Developer, Web Developer (MCPD), Microsoft Certified Technology Specialist, .NET Framework 2.0 Web (MCTS). I am a Reviewer for several refereed journals and international conferences, such as IEEE Transactions on Biomedical Engineering, IEEE Transactions on Industrial Electronics, Optic Letters, Measurement Science Review, and also a member of the International Advisory Committee for 2012 IEEE Business Engineering and Industrial Applications and 2012 IEEE Symposium on Business, Engineering and Industrial Applications.",institutionString:null,institution:{name:"Joseph Fourier University",country:{name:"France"}}},{id:"55578",title:"Dr.",name:"Antonio",middleName:null,surname:"Jurado-Navas",slug:"antonio-jurado-navas",fullName:"Antonio Jurado-Navas",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/55578/images/4574_n.png",biography:"Antonio Jurado-Navas received the M.S. degree (2002) and the Ph.D. degree (2009) in Telecommunication Engineering, both from the University of Málaga (Spain). He first worked as a consultant at Vodafone-Spain. From 2004 to 2011, he was a Research Assistant with the Communications Engineering Department at the University of Málaga. In 2011, he became an Assistant Professor in the same department. From 2012 to 2015, he was with Ericsson Spain, where he was working on geo-location\ntools for third generation mobile networks. Since 2015, he is a Marie-Curie fellow at the Denmark Technical University. His current research interests include the areas of mobile communication systems and channel modeling in addition to atmospheric optical communications, adaptive optics and statistics",institutionString:null,institution:{name:"University of Malaga",country:{name:"Spain"}}}],filtersByRegion:[{group:"region",caption:"North America",value:1,count:5766},{group:"region",caption:"Middle and South America",value:2,count:5228},{group:"region",caption:"Africa",value:3,count:1717},{group:"region",caption:"Asia",value:4,count:10370},{group:"region",caption:"Australia and Oceania",value:5,count:897},{group:"region",caption:"Europe",value:6,count:15790}],offset:12,limit:12,total:118192},chapterEmbeded:{data:{}},editorApplication:{success:null,errors:{}},ofsBooks:{filterParams:{sort:"dateEndThirdStepPublish",topicId:"5"},books:[{type:"book",id:"10748",title:"Fishery",subtitle:null,isOpenForSubmission:!0,hash:"ecde44e36545a02e9bed47333869ca6f",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10748.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10738",title:"Molluscs",subtitle:null,isOpenForSubmission:!0,hash:"a42a81ed3f9e3dda6d0daaf69c26117e",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10738.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10768",title:"Bryology and Lichenology",subtitle:null,isOpenForSubmission:!0,hash:"2188e0dffab6ad8d6c0f3afce29ccce0",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10768.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10834",title:"Invertebrate Neurophysiology",subtitle:null,isOpenForSubmission:!0,hash:"d3831987f0552c07015057f170cab45c",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10834.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10885",title:"Snake Biology",subtitle:null,isOpenForSubmission:!0,hash:"78f81673958ec92284b94aee280896bf",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10885.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10895",title:"Grasses and Grassland",subtitle:null,isOpenForSubmission:!0,hash:"4abcdc7f2d889b2c8c96f7066899e974",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10895.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9662",title:"Vegetation Index and Dynamics",subtitle:null,isOpenForSubmission:!0,hash:"0abf2a59ee63fc1ba4fb64d77c9b1be7",slug:null,bookSignature:"Dr. Eusebio Cano Carmona, Dr. Ricardo Quinto Canas, Dr. Ana Cano Ortiz and Dr. Carmelo Maria Musarella",coverURL:"https://cdn.intechopen.com/books/images_new/9662.jpg",editedByType:null,editors:[{id:"87846",title:"Dr.",name:"Eusebio",surname:"Cano Carmona",slug:"eusebio-cano-carmona",fullName:"Eusebio Cano Carmona"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10557",title:"Elaeis guineensis",subtitle:null,isOpenForSubmission:!0,hash:"79500ab1930271876b4e0575e2ed3966",slug:null,bookSignature:"Dr. Hesam Kamyab",coverURL:"https://cdn.intechopen.com/books/images_new/10557.jpg",editedByType:null,editors:[{id:"225957",title:"Dr.",name:"Hesam",surname:"Kamyab",slug:"hesam-kamyab",fullName:"Hesam Kamyab"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10218",title:"Flagellar Motility in Cells",subtitle:null,isOpenForSubmission:!0,hash:"5fcc15570365a82d9f2c4816f4e0ee2e",slug:null,bookSignature:"Prof. Yusuf Bozkurt",coverURL:"https://cdn.intechopen.com/books/images_new/10218.jpg",editedByType:null,editors:[{id:"90846",title:"Prof.",name:"Yusuf",surname:"Bozkurt",slug:"yusuf-bozkurt",fullName:"Yusuf Bozkurt"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10750",title:"Solanum tuberosum - a Promising Crop for Starvation Problem",subtitle:null,isOpenForSubmission:!0,hash:"516eb729eadf0d1a9d1d2e6bf31e8e9c",slug:null,bookSignature:"Prof. Mustafa Yildiz and Dr. Yasin Ozgen",coverURL:"https://cdn.intechopen.com/books/images_new/10750.jpg",editedByType:null,editors:[{id:"141637",title:"Prof.",name:"Mustafa",surname:"Yildiz",slug:"mustafa-yildiz",fullName:"Mustafa Yildiz"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10737",title:"Equus",subtitle:null,isOpenForSubmission:!0,hash:"258ffafc92a7c9550bb85f004d7402e7",slug:null,bookSignature:"Associate Prof. Adriana Pires Neves",coverURL:"https://cdn.intechopen.com/books/images_new/10737.jpg",editedByType:null,editors:[{id:"188768",title:"Associate Prof.",name:"Adriana",surname:"Pires Neves",slug:"adriana-pires-neves",fullName:"Adriana Pires Neves"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10772",title:"Parasitic Plants",subtitle:null,isOpenForSubmission:!0,hash:"31abd439b5674c91d18ad77dbc52500f",slug:null,bookSignature:"Dr. Ana Maria Gonzalez and Dr. Hector Sato",coverURL:"https://cdn.intechopen.com/books/images_new/10772.jpg",editedByType:null,editors:[{id:"281854",title:"Dr.",name:"Ana Maria",surname:"Gonzalez",slug:"ana-maria-gonzalez",fullName:"Ana Maria Gonzalez"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],filtersByTopic:[{group:"topic",caption:"Agricultural and Biological Sciences",value:5,count:16},{group:"topic",caption:"Biochemistry, Genetics and Molecular Biology",value:6,count:4},{group:"topic",caption:"Business, Management and Economics",value:7,count:1},{group:"topic",caption:"Chemistry",value:8,count:8},{group:"topic",caption:"Computer and Information Science",value:9,count:6},{group:"topic",caption:"Earth and Planetary Sciences",value:10,count:7},{group:"topic",caption:"Engineering",value:11,count:16},{group:"topic",caption:"Environmental Sciences",value:12,count:2},{group:"topic",caption:"Immunology and Microbiology",value:13,count:3},{group:"topic",caption:"Materials Science",value:14,count:5},{group:"topic",caption:"Mathematics",value:15,count:1},{group:"topic",caption:"Medicine",value:16,count:24},{group:"topic",caption:"Neuroscience",value:18,count:1},{group:"topic",caption:"Pharmacology, Toxicology and Pharmaceutical Science",value:19,count:3},{group:"topic",caption:"Physics",value:20,count:3},{group:"topic",caption:"Psychology",value:21,count:4},{group:"topic",caption:"Robotics",value:22,count:1},{group:"topic",caption:"Social Sciences",value:23,count:3},{group:"topic",caption:"Technology",value:24,count:1},{group:"topic",caption:"Veterinary Medicine and Science",value:25,count:1}],offset:12,limit:12,total:22},popularBooks:{featuredBooks:[{type:"book",id:"9385",title:"Renewable Energy",subtitle:"Technologies and Applications",isOpenForSubmission:!1,hash:"a6b446d19166f17f313008e6c056f3d8",slug:"renewable-energy-technologies-and-applications",bookSignature:"Tolga Taner, Archana Tiwari and Taha Selim Ustun",coverURL:"https://cdn.intechopen.com/books/images_new/9385.jpg",editors:[{id:"197240",title:"Associate Prof.",name:"Tolga",middleName:null,surname:"Taner",slug:"tolga-taner",fullName:"Tolga Taner"}],equalEditorOne:{id:"186791",title:"Dr.",name:"Archana",middleName:null,surname:"Tiwari",slug:"archana-tiwari",fullName:"Archana Tiwari",profilePictureURL:"https://mts.intechopen.com/storage/users/186791/images/system/186791.jpg",biography:"Dr. Archana Tiwari is Associate Professor at Amity University, India. Her research interests include renewable sources of energy from microalgae and further utilizing the residual biomass for the generation of value-added products, bioremediation through microalgae and microbial consortium, antioxidative enzymes and stress, and nutraceuticals from microalgae. She has been working on algal biotechnology for the last two decades. She has published her research in many international journals and has authored many books and chapters with renowned publishing houses. She has also delivered talks as an invited speaker at many national and international conferences. Dr. Tiwari is the recipient of several awards including Researcher of the Year and Distinguished Scientist.",institutionString:"Amity University",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"1",institution:{name:"Amity University",institutionURL:null,country:{name:"India"}}},equalEditorTwo:{id:"197609",title:"Prof.",name:"Taha Selim",middleName:null,surname:"Ustun",slug:"taha-selim-ustun",fullName:"Taha Selim Ustun",profilePictureURL:"https://mts.intechopen.com/storage/users/197609/images/system/197609.jpeg",biography:"Dr. Taha Selim Ustun received a Ph.D. in Electrical Engineering from Victoria University, Melbourne, Australia. He is a researcher with the Fukushima Renewable Energy Institute, AIST (FREA), where he leads the Smart Grid Cybersecurity Laboratory. Prior to that, he was a faculty member with the School of Electrical and Computer Engineering, Carnegie Mellon University, Pittsburgh, PA, USA. His current research interests include power systems protection, communication in power networks, distributed generation, microgrids, electric vehicle integration, and cybersecurity in smart grids. He serves on the editorial boards of IEEE Access, IEEE Transactions on Industrial Informatics, Energies, Electronics, Electricity, World Electric Vehicle and Information journals. Dr. Ustun is a member of the IEEE 2004 and 2800, IEC Renewable Energy Management WG 8, and IEC TC 57 WG17. He has been invited to run specialist courses in Africa, India, and China. He has delivered talks for the Qatar Foundation, the World Energy Council, the Waterloo Global Science Initiative, and the European Union Energy Initiative (EUEI). His research has attracted funding from prestigious programs in Japan, Australia, the European Union, and North America.",institutionString:"Fukushima Renewable Energy Institute, AIST (FREA)",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"1",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"National Institute of Advanced Industrial Science and Technology",institutionURL:null,country:{name:"Japan"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10065",title:"Wavelet Theory",subtitle:null,isOpenForSubmission:!1,hash:"d8868e332169597ba2182d9b004d60de",slug:"wavelet-theory",bookSignature:"Somayeh Mohammady",coverURL:"https://cdn.intechopen.com/books/images_new/10065.jpg",editors:[{id:"109280",title:"Dr.",name:"Somayeh",middleName:null,surname:"Mohammady",slug:"somayeh-mohammady",fullName:"Somayeh Mohammady"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9644",title:"Glaciers and the Polar Environment",subtitle:null,isOpenForSubmission:!1,hash:"e8cfdc161794e3753ced54e6ff30873b",slug:"glaciers-and-the-polar-environment",bookSignature:"Masaki Kanao, Danilo Godone and Niccolò Dematteis",coverURL:"https://cdn.intechopen.com/books/images_new/9644.jpg",editors:[{id:"51959",title:"Dr.",name:"Masaki",middleName:null,surname:"Kanao",slug:"masaki-kanao",fullName:"Masaki Kanao"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8985",title:"Natural Resources Management and Biological Sciences",subtitle:null,isOpenForSubmission:!1,hash:"5c2e219a6c021a40b5a20c041dea88c4",slug:"natural-resources-management-and-biological-sciences",bookSignature:"Edward R. Rhodes and Humood Naser",coverURL:"https://cdn.intechopen.com/books/images_new/8985.jpg",editors:[{id:"280886",title:"Prof.",name:"Edward R",middleName:null,surname:"Rhodes",slug:"edward-r-rhodes",fullName:"Edward R Rhodes"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9671",title:"Macrophages",subtitle:null,isOpenForSubmission:!1,hash:"03b00fdc5f24b71d1ecdfd75076bfde6",slug:"macrophages",bookSignature:"Hridayesh Prakash",coverURL:"https://cdn.intechopen.com/books/images_new/9671.jpg",editors:[{id:"287184",title:"Dr.",name:"Hridayesh",middleName:null,surname:"Prakash",slug:"hridayesh-prakash",fullName:"Hridayesh Prakash"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9313",title:"Clay Science and Technology",subtitle:null,isOpenForSubmission:!1,hash:"6fa7e70396ff10620e032bb6cfa6fb72",slug:"clay-science-and-technology",bookSignature:"Gustavo Morari Do Nascimento",coverURL:"https://cdn.intechopen.com/books/images_new/9313.jpg",editors:[{id:"7153",title:"Prof.",name:"Gustavo",middleName:null,surname:"Morari Do Nascimento",slug:"gustavo-morari-do-nascimento",fullName:"Gustavo Morari Do Nascimento"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9888",title:"Nuclear Power Plants",subtitle:"The Processes from the Cradle to the Grave",isOpenForSubmission:!1,hash:"c2c8773e586f62155ab8221ebb72a849",slug:"nuclear-power-plants-the-processes-from-the-cradle-to-the-grave",bookSignature:"Nasser Awwad",coverURL:"https://cdn.intechopen.com/books/images_new/9888.jpg",editors:[{id:"145209",title:"Prof.",name:"Nasser",middleName:"S",surname:"Awwad",slug:"nasser-awwad",fullName:"Nasser Awwad"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9027",title:"Human Blood Group Systems and Haemoglobinopathies",subtitle:null,isOpenForSubmission:!1,hash:"d00d8e40b11cfb2547d1122866531c7e",slug:"human-blood-group-systems-and-haemoglobinopathies",bookSignature:"Osaro Erhabor and Anjana Munshi",coverURL:"https://cdn.intechopen.com/books/images_new/9027.jpg",editors:[{id:"35140",title:null,name:"Osaro",middleName:null,surname:"Erhabor",slug:"osaro-erhabor",fullName:"Osaro Erhabor"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7841",title:"New Insights Into Metabolic Syndrome",subtitle:null,isOpenForSubmission:!1,hash:"ef5accfac9772b9e2c9eff884f085510",slug:"new-insights-into-metabolic-syndrome",bookSignature:"Akikazu Takada",coverURL:"https://cdn.intechopen.com/books/images_new/7841.jpg",editors:[{id:"248459",title:"Dr.",name:"Akikazu",middleName:null,surname:"Takada",slug:"akikazu-takada",fullName:"Akikazu Takada"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8558",title:"Aerodynamics",subtitle:null,isOpenForSubmission:!1,hash:"db7263fc198dfb539073ba0260a7f1aa",slug:"aerodynamics",bookSignature:"Mofid Gorji-Bandpy and Aly-Mousaad Aly",coverURL:"https://cdn.intechopen.com/books/images_new/8558.jpg",editors:[{id:"35542",title:"Prof.",name:"Mofid",middleName:null,surname:"Gorji-Bandpy",slug:"mofid-gorji-bandpy",fullName:"Mofid Gorji-Bandpy"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7847",title:"Medical Toxicology",subtitle:null,isOpenForSubmission:!1,hash:"db9b65bea093de17a0855a1b27046247",slug:"medical-toxicology",bookSignature:"Pınar Erkekoglu and Tomohisa Ogawa",coverURL:"https://cdn.intechopen.com/books/images_new/7847.jpg",editors:[{id:"109978",title:"Prof.",name:"Pınar",middleName:null,surname:"Erkekoglu",slug:"pinar-erkekoglu",fullName:"Pınar Erkekoglu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10432",title:"Casting Processes and Modelling of Metallic Materials",subtitle:null,isOpenForSubmission:!1,hash:"2c5c9df938666bf5d1797727db203a6d",slug:"casting-processes-and-modelling-of-metallic-materials",bookSignature:"Zakaria Abdallah and Nada Aldoumani",coverURL:"https://cdn.intechopen.com/books/images_new/10432.jpg",editors:[{id:"201670",title:"Dr.",name:"Zak",middleName:null,surname:"Abdallah",slug:"zak-abdallah",fullName:"Zak Abdallah"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:12,limit:12,total:5238},hotBookTopics:{hotBooks:[],offset:0,limit:12,total:null},publish:{},publishingProposal:{success:null,errors:{}},books:{featuredBooks:[{type:"book",id:"10065",title:"Wavelet Theory",subtitle:null,isOpenForSubmission:!1,hash:"d8868e332169597ba2182d9b004d60de",slug:"wavelet-theory",bookSignature:"Somayeh Mohammady",coverURL:"https://cdn.intechopen.com/books/images_new/10065.jpg",editors:[{id:"109280",title:"Dr.",name:"Somayeh",middleName:null,surname:"Mohammady",slug:"somayeh-mohammady",fullName:"Somayeh Mohammady"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9644",title:"Glaciers and the Polar Environment",subtitle:null,isOpenForSubmission:!1,hash:"e8cfdc161794e3753ced54e6ff30873b",slug:"glaciers-and-the-polar-environment",bookSignature:"Masaki Kanao, Danilo Godone and Niccolò Dematteis",coverURL:"https://cdn.intechopen.com/books/images_new/9644.jpg",editors:[{id:"51959",title:"Dr.",name:"Masaki",middleName:null,surname:"Kanao",slug:"masaki-kanao",fullName:"Masaki Kanao"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9385",title:"Renewable Energy",subtitle:"Technologies and Applications",isOpenForSubmission:!1,hash:"a6b446d19166f17f313008e6c056f3d8",slug:"renewable-energy-technologies-and-applications",bookSignature:"Tolga Taner, Archana Tiwari and Taha Selim Ustun",coverURL:"https://cdn.intechopen.com/books/images_new/9385.jpg",editors:[{id:"197240",title:"Associate Prof.",name:"Tolga",middleName:null,surname:"Taner",slug:"tolga-taner",fullName:"Tolga Taner"}],equalEditorOne:{id:"186791",title:"Dr.",name:"Archana",middleName:null,surname:"Tiwari",slug:"archana-tiwari",fullName:"Archana Tiwari",profilePictureURL:"https://mts.intechopen.com/storage/users/186791/images/system/186791.jpg",biography:"Dr. Archana Tiwari is Associate Professor at Amity University, India. Her research interests include renewable sources of energy from microalgae and further utilizing the residual biomass for the generation of value-added products, bioremediation through microalgae and microbial consortium, antioxidative enzymes and stress, and nutraceuticals from microalgae. She has been working on algal biotechnology for the last two decades. She has published her research in many international journals and has authored many books and chapters with renowned publishing houses. She has also delivered talks as an invited speaker at many national and international conferences. Dr. Tiwari is the recipient of several awards including Researcher of the Year and Distinguished Scientist.",institutionString:"Amity University",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"1",institution:{name:"Amity University",institutionURL:null,country:{name:"India"}}},equalEditorTwo:{id:"197609",title:"Prof.",name:"Taha Selim",middleName:null,surname:"Ustun",slug:"taha-selim-ustun",fullName:"Taha Selim Ustun",profilePictureURL:"https://mts.intechopen.com/storage/users/197609/images/system/197609.jpeg",biography:"Dr. Taha Selim Ustun received a Ph.D. in Electrical Engineering from Victoria University, Melbourne, Australia. He is a researcher with the Fukushima Renewable Energy Institute, AIST (FREA), where he leads the Smart Grid Cybersecurity Laboratory. Prior to that, he was a faculty member with the School of Electrical and Computer Engineering, Carnegie Mellon University, Pittsburgh, PA, USA. His current research interests include power systems protection, communication in power networks, distributed generation, microgrids, electric vehicle integration, and cybersecurity in smart grids. He serves on the editorial boards of IEEE Access, IEEE Transactions on Industrial Informatics, Energies, Electronics, Electricity, World Electric Vehicle and Information journals. Dr. Ustun is a member of the IEEE 2004 and 2800, IEC Renewable Energy Management WG 8, and IEC TC 57 WG17. He has been invited to run specialist courses in Africa, India, and China. He has delivered talks for the Qatar Foundation, the World Energy Council, the Waterloo Global Science Initiative, and the European Union Energy Initiative (EUEI). His research has attracted funding from prestigious programs in Japan, Australia, the European Union, and North America.",institutionString:"Fukushima Renewable Energy Institute, AIST (FREA)",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"1",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"National Institute of Advanced Industrial Science and Technology",institutionURL:null,country:{name:"Japan"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8985",title:"Natural Resources Management and Biological Sciences",subtitle:null,isOpenForSubmission:!1,hash:"5c2e219a6c021a40b5a20c041dea88c4",slug:"natural-resources-management-and-biological-sciences",bookSignature:"Edward R. Rhodes and Humood Naser",coverURL:"https://cdn.intechopen.com/books/images_new/8985.jpg",editors:[{id:"280886",title:"Prof.",name:"Edward R",middleName:null,surname:"Rhodes",slug:"edward-r-rhodes",fullName:"Edward R Rhodes"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9671",title:"Macrophages",subtitle:null,isOpenForSubmission:!1,hash:"03b00fdc5f24b71d1ecdfd75076bfde6",slug:"macrophages",bookSignature:"Hridayesh Prakash",coverURL:"https://cdn.intechopen.com/books/images_new/9671.jpg",editors:[{id:"287184",title:"Dr.",name:"Hridayesh",middleName:null,surname:"Prakash",slug:"hridayesh-prakash",fullName:"Hridayesh Prakash"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9313",title:"Clay Science and Technology",subtitle:null,isOpenForSubmission:!1,hash:"6fa7e70396ff10620e032bb6cfa6fb72",slug:"clay-science-and-technology",bookSignature:"Gustavo Morari Do Nascimento",coverURL:"https://cdn.intechopen.com/books/images_new/9313.jpg",editors:[{id:"7153",title:"Prof.",name:"Gustavo",middleName:null,surname:"Morari Do Nascimento",slug:"gustavo-morari-do-nascimento",fullName:"Gustavo Morari Do Nascimento"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9888",title:"Nuclear Power Plants",subtitle:"The Processes from the Cradle to the Grave",isOpenForSubmission:!1,hash:"c2c8773e586f62155ab8221ebb72a849",slug:"nuclear-power-plants-the-processes-from-the-cradle-to-the-grave",bookSignature:"Nasser Awwad",coverURL:"https://cdn.intechopen.com/books/images_new/9888.jpg",editors:[{id:"145209",title:"Prof.",name:"Nasser",middleName:"S",surname:"Awwad",slug:"nasser-awwad",fullName:"Nasser Awwad"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9027",title:"Human Blood Group Systems and Haemoglobinopathies",subtitle:null,isOpenForSubmission:!1,hash:"d00d8e40b11cfb2547d1122866531c7e",slug:"human-blood-group-systems-and-haemoglobinopathies",bookSignature:"Osaro Erhabor and Anjana Munshi",coverURL:"https://cdn.intechopen.com/books/images_new/9027.jpg",editors:[{id:"35140",title:null,name:"Osaro",middleName:null,surname:"Erhabor",slug:"osaro-erhabor",fullName:"Osaro Erhabor"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10432",title:"Casting Processes and Modelling of Metallic Materials",subtitle:null,isOpenForSubmission:!1,hash:"2c5c9df938666bf5d1797727db203a6d",slug:"casting-processes-and-modelling-of-metallic-materials",bookSignature:"Zakaria Abdallah and Nada Aldoumani",coverURL:"https://cdn.intechopen.com/books/images_new/10432.jpg",editors:[{id:"201670",title:"Dr.",name:"Zak",middleName:null,surname:"Abdallah",slug:"zak-abdallah",fullName:"Zak Abdallah"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7841",title:"New Insights Into Metabolic Syndrome",subtitle:null,isOpenForSubmission:!1,hash:"ef5accfac9772b9e2c9eff884f085510",slug:"new-insights-into-metabolic-syndrome",bookSignature:"Akikazu Takada",coverURL:"https://cdn.intechopen.com/books/images_new/7841.jpg",editors:[{id:"248459",title:"Dr.",name:"Akikazu",middleName:null,surname:"Takada",slug:"akikazu-takada",fullName:"Akikazu Takada"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],latestBooks:[{type:"book",id:"9550",title:"Entrepreneurship",subtitle:"Contemporary Issues",isOpenForSubmission:!1,hash:"9b4ac1ee5b743abf6f88495452b1e5e7",slug:"entrepreneurship-contemporary-issues",bookSignature:"Mladen Turuk",coverURL:"https://cdn.intechopen.com/books/images_new/9550.jpg",editedByType:"Edited by",editors:[{id:"319755",title:"Prof.",name:"Mladen",middleName:null,surname:"Turuk",slug:"mladen-turuk",fullName:"Mladen Turuk"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10065",title:"Wavelet Theory",subtitle:null,isOpenForSubmission:!1,hash:"d8868e332169597ba2182d9b004d60de",slug:"wavelet-theory",bookSignature:"Somayeh Mohammady",coverURL:"https://cdn.intechopen.com/books/images_new/10065.jpg",editedByType:"Edited by",editors:[{id:"109280",title:"Dr.",name:"Somayeh",middleName:null,surname:"Mohammady",slug:"somayeh-mohammady",fullName:"Somayeh Mohammady"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9313",title:"Clay Science and Technology",subtitle:null,isOpenForSubmission:!1,hash:"6fa7e70396ff10620e032bb6cfa6fb72",slug:"clay-science-and-technology",bookSignature:"Gustavo Morari Do Nascimento",coverURL:"https://cdn.intechopen.com/books/images_new/9313.jpg",editedByType:"Edited by",editors:[{id:"7153",title:"Prof.",name:"Gustavo",middleName:null,surname:"Morari Do Nascimento",slug:"gustavo-morari-do-nascimento",fullName:"Gustavo Morari Do Nascimento"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9888",title:"Nuclear Power Plants",subtitle:"The Processes from the Cradle to the Grave",isOpenForSubmission:!1,hash:"c2c8773e586f62155ab8221ebb72a849",slug:"nuclear-power-plants-the-processes-from-the-cradle-to-the-grave",bookSignature:"Nasser Awwad",coverURL:"https://cdn.intechopen.com/books/images_new/9888.jpg",editedByType:"Edited by",editors:[{id:"145209",title:"Prof.",name:"Nasser",middleName:"S",surname:"Awwad",slug:"nasser-awwad",fullName:"Nasser Awwad"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8098",title:"Resources of Water",subtitle:null,isOpenForSubmission:!1,hash:"d251652996624d932ef7b8ed62cf7cfc",slug:"resources-of-water",bookSignature:"Prathna Thanjavur Chandrasekaran, Muhammad Salik Javaid, Aftab Sadiq",coverURL:"https://cdn.intechopen.com/books/images_new/8098.jpg",editedByType:"Edited by",editors:[{id:"167917",title:"Dr.",name:"Prathna",middleName:null,surname:"Thanjavur Chandrasekaran",slug:"prathna-thanjavur-chandrasekaran",fullName:"Prathna Thanjavur Chandrasekaran"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9644",title:"Glaciers and the Polar Environment",subtitle:null,isOpenForSubmission:!1,hash:"e8cfdc161794e3753ced54e6ff30873b",slug:"glaciers-and-the-polar-environment",bookSignature:"Masaki Kanao, Danilo Godone and Niccolò Dematteis",coverURL:"https://cdn.intechopen.com/books/images_new/9644.jpg",editedByType:"Edited by",editors:[{id:"51959",title:"Dr.",name:"Masaki",middleName:null,surname:"Kanao",slug:"masaki-kanao",fullName:"Masaki Kanao"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10432",title:"Casting Processes and Modelling of Metallic Materials",subtitle:null,isOpenForSubmission:!1,hash:"2c5c9df938666bf5d1797727db203a6d",slug:"casting-processes-and-modelling-of-metallic-materials",bookSignature:"Zakaria Abdallah and Nada Aldoumani",coverURL:"https://cdn.intechopen.com/books/images_new/10432.jpg",editedByType:"Edited by",editors:[{id:"201670",title:"Dr.",name:"Zak",middleName:null,surname:"Abdallah",slug:"zak-abdallah",fullName:"Zak Abdallah"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9671",title:"Macrophages",subtitle:null,isOpenForSubmission:!1,hash:"03b00fdc5f24b71d1ecdfd75076bfde6",slug:"macrophages",bookSignature:"Hridayesh Prakash",coverURL:"https://cdn.intechopen.com/books/images_new/9671.jpg",editedByType:"Edited by",editors:[{id:"287184",title:"Dr.",name:"Hridayesh",middleName:null,surname:"Prakash",slug:"hridayesh-prakash",fullName:"Hridayesh Prakash"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8415",title:"Extremophilic Microbes and Metabolites",subtitle:"Diversity, Bioprospecting and Biotechnological Applications",isOpenForSubmission:!1,hash:"93e0321bc93b89ff73730157738f8f97",slug:"extremophilic-microbes-and-metabolites-diversity-bioprospecting-and-biotechnological-applications",bookSignature:"Afef Najjari, Ameur Cherif, Haïtham Sghaier and Hadda Imene Ouzari",coverURL:"https://cdn.intechopen.com/books/images_new/8415.jpg",editedByType:"Edited by",editors:[{id:"196823",title:"Dr.",name:"Afef",middleName:null,surname:"Najjari",slug:"afef-najjari",fullName:"Afef Najjari"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9731",title:"Oxidoreductase",subtitle:null,isOpenForSubmission:!1,hash:"852e6f862c85fc3adecdbaf822e64e6e",slug:"oxidoreductase",bookSignature:"Mahmoud Ahmed Mansour",coverURL:"https://cdn.intechopen.com/books/images_new/9731.jpg",editedByType:"Edited by",editors:[{id:"224662",title:"Prof.",name:"Mahmoud Ahmed",middleName:null,surname:"Mansour",slug:"mahmoud-ahmed-mansour",fullName:"Mahmoud Ahmed Mansour"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},subject:{topic:{id:"858",title:"Biofuels",slug:"environmental-sciences-environmental-management-biofuels",parent:{title:"Environmental Management",slug:"environmental-sciences-environmental-management"},numberOfBooks:1,numberOfAuthorsAndEditors:46,numberOfWosCitations:130,numberOfCrossrefCitations:39,numberOfDimensionsCitations:133,videoUrl:null,fallbackUrl:null,description:null},booksByTopicFilter:{topicSlug:"environmental-sciences-environmental-management-biofuels",sort:"-publishedDate",limit:12,offset:0},booksByTopicCollection:[{type:"book",id:"324",title:"Bioethanol",subtitle:null,isOpenForSubmission:!1,hash:"8b4842c55f8a1470b59fde5f49952ecd",slug:"bioethanol",bookSignature:"Marco Aurelio Pinheiro Lima and Alexandra Pardo Policastro Natalense",coverURL:"https://cdn.intechopen.com/books/images_new/324.jpg",editedByType:"Edited by",editors:[{id:"60496",title:"Prof.",name:"Marco Aurelio",middleName:null,surname:"Pinheiro Lima",slug:"marco-aurelio-pinheiro-lima",fullName:"Marco Aurelio Pinheiro Lima"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],booksByTopicTotal:1,mostCitedChapters:[{id:"27352",doi:"10.5772/23987",title:"Hydrolysis of Lignocellulosic Biomass: Current Status of Processes and Technologies and Future Perspectives",slug:"hydrolysis-of-lignocellulosic-biomass-current-status-of-processes-and-technologies-and-future-perspe",totalDownloads:9169,totalCrossrefCites:28,totalDimensionsCites:63,book:{slug:"bioethanol",title:"Bioethanol",fullTitle:"Bioethanol"},signatures:"Alessandra Verardi, Isabella De Bari, Emanuele Ricca and Vincenza Calabrò",authors:[{id:"54789",title:"Dr.",name:"Isabella",middleName:null,surname:"De Bari",slug:"isabella-de-bari",fullName:"Isabella De Bari"},{id:"54793",title:"Dr.",name:"Alessandra",middleName:null,surname:"Verardi",slug:"alessandra-verardi",fullName:"Alessandra Verardi"},{id:"54794",title:"Dr.",name:"Emanuele",middleName:null,surname:"Ricca",slug:"emanuele-ricca",fullName:"Emanuele Ricca"},{id:"54795",title:"Prof.",name:"Vincenza",middleName:null,surname:"Calabrň",slug:"vincenza-calabrn",fullName:"Vincenza Calabrň"}]},{id:"27350",doi:"10.5772/20489",title:"Sorghum as a Multifunctional Crop for the Production of Fuel Ethanol: Current Status and Future Trends",slug:"sorghum-as-a-multifunctional-crop-for-the-production-of-fuel-ethanol-current-status-and-future-trend",totalDownloads:4573,totalCrossrefCites:0,totalDimensionsCites:21,book:{slug:"bioethanol",title:"Bioethanol",fullTitle:"Bioethanol"},signatures:"Sergio O. Serna-Saldívar, Cristina Chuck-Hernández, Esther Pérez-Carrillo and Erick Heredia-Olea",authors:[{id:"39203",title:"Dr.",name:"Sergio",middleName:"O.",surname:"Serna-Saldivar",slug:"sergio-serna-saldivar",fullName:"Sergio Serna-Saldivar"},{id:"94103",title:"Ms.",name:"Cristina",middleName:null,surname:"Chuck-Hernandez",slug:"cristina-chuck-hernandez",fullName:"Cristina Chuck-Hernandez"},{id:"94104",title:"Dr.",name:"Esther",middleName:null,surname:"Perez-Carrillo",slug:"esther-perez-carrillo",fullName:"Esther Perez-Carrillo"},{id:"94105",title:"Mr.",name:"Erick",middleName:null,surname:"Heredia-Olea",slug:"erick-heredia-olea",fullName:"Erick Heredia-Olea"}]},{id:"27348",doi:"10.5772/23112",title:"Cassava Bioethanol",slug:"-cassava-bioethanol",totalDownloads:9851,totalCrossrefCites:3,totalDimensionsCites:13,book:{slug:"bioethanol",title:"Bioethanol",fullTitle:"Bioethanol"},signatures:"Klanarong Sriroth, Sittichoke Wanlapatit and Kuakoon Piyachomkwan",authors:[{id:"50646",title:"Dr.",name:"Klanarong",middleName:null,surname:"Sriroth",slug:"klanarong-sriroth",fullName:"Klanarong Sriroth"},{id:"58635",title:"Dr.",name:"Kuakoon",middleName:null,surname:"Piyachomkwan",slug:"kuakoon-piyachomkwan",fullName:"Kuakoon Piyachomkwan"}]}],mostDownloadedChaptersLast30Days:[{id:"27348",title:"Cassava Bioethanol",slug:"-cassava-bioethanol",totalDownloads:9848,totalCrossrefCites:3,totalDimensionsCites:13,book:{slug:"bioethanol",title:"Bioethanol",fullTitle:"Bioethanol"},signatures:"Klanarong Sriroth, Sittichoke Wanlapatit and Kuakoon Piyachomkwan",authors:[{id:"50646",title:"Dr.",name:"Klanarong",middleName:null,surname:"Sriroth",slug:"klanarong-sriroth",fullName:"Klanarong Sriroth"},{id:"58635",title:"Dr.",name:"Kuakoon",middleName:null,surname:"Piyachomkwan",slug:"kuakoon-piyachomkwan",fullName:"Kuakoon Piyachomkwan"}]},{id:"27357",title:"SSF Fermentation of Rape Straw and the Effects of Inhibitory Stress on Yeast",slug:"ssf-fermentation-of-rape-straw-and-the-effects-of-inhibitory-stress-on-yeast",totalDownloads:2842,totalCrossrefCites:1,totalDimensionsCites:4,book:{slug:"bioethanol",title:"Bioethanol",fullTitle:"Bioethanol"},signatures:"Anders Thygesen, Lasse Vahlgren, Jens Heller Frederiksen, William Linnane and Mette H. Thomsen",authors:[{id:"57427",title:"Dr.",name:"Anders",middleName:null,surname:"Thygesen",slug:"anders-thygesen",fullName:"Anders Thygesen"},{id:"62893",title:"Mr",name:"Lasse",middleName:null,surname:"Vahlgren",slug:"lasse-vahlgren",fullName:"Lasse Vahlgren"},{id:"98319",title:"Mr.",name:"Jens Heller",middleName:null,surname:"Frederiksen",slug:"jens-heller-frederiksen",fullName:"Jens Heller Frederiksen"},{id:"98323",title:"Dr.",name:"William",middleName:null,surname:"Linnane",slug:"william-linnane",fullName:"William Linnane"},{id:"98325",title:"Dr.",name:"Mette Hedegaard",middleName:null,surname:"Thomsen",slug:"mette-hedegaard-thomsen",fullName:"Mette Hedegaard Thomsen"}]},{id:"27351",title:"Simultaneous Production of Sugar and Ethanol from Sugarcane in China, the Development, Research and Prospect Aspects",slug:"simultaneous-production-of-sugar-and-ethanol-from-sugarcane-the-process-technical-and-economic-aspec",totalDownloads:7875,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"bioethanol",title:"Bioethanol",fullTitle:"Bioethanol"},signatures:"Lei Liang, Riyi Xu, Qiwei Li, Xiangyang Huang, Yuxing An, Yuanping Zhang and Yishan Guo",authors:[{id:"45746",title:"Dr.",name:"Lei",middleName:null,surname:"Liang",slug:"lei-liang",fullName:"Lei Liang"},{id:"54152",title:"Prof.",name:"Qi Wei",middleName:null,surname:"Li",slug:"qi-wei-li",fullName:"Qi Wei Li"},{id:"54153",title:"Prof.",name:"Xiang Yang",middleName:null,surname:"Huang",slug:"xiang-yang-huang",fullName:"Xiang Yang Huang"},{id:"54154",title:"Prof.",name:"Yuxing",middleName:null,surname:"An",slug:"yuxing-an",fullName:"Yuxing An"},{id:"54180",title:"Ms",name:"Yuangping",middleName:null,surname:"Zhang",slug:"yuangping-zhang",fullName:"Yuangping Zhang"}]},{id:"27352",title:"Hydrolysis of Lignocellulosic Biomass: Current Status of Processes and Technologies and Future Perspectives",slug:"hydrolysis-of-lignocellulosic-biomass-current-status-of-processes-and-technologies-and-future-perspe",totalDownloads:9168,totalCrossrefCites:28,totalDimensionsCites:63,book:{slug:"bioethanol",title:"Bioethanol",fullTitle:"Bioethanol"},signatures:"Alessandra Verardi, Isabella De Bari, Emanuele Ricca and Vincenza Calabrò",authors:[{id:"54789",title:"Dr.",name:"Isabella",middleName:null,surname:"De Bari",slug:"isabella-de-bari",fullName:"Isabella De Bari"},{id:"54793",title:"Dr.",name:"Alessandra",middleName:null,surname:"Verardi",slug:"alessandra-verardi",fullName:"Alessandra Verardi"},{id:"54794",title:"Dr.",name:"Emanuele",middleName:null,surname:"Ricca",slug:"emanuele-ricca",fullName:"Emanuele Ricca"},{id:"54795",title:"Prof.",name:"Vincenza",middleName:null,surname:"Calabrň",slug:"vincenza-calabrn",fullName:"Vincenza Calabrň"}]},{id:"27360",title:"Catalytic Hydrogen Production from Bioethanol",slug:"catalytic-hydrogen-production-from-bioethanol",totalDownloads:3693,totalCrossrefCites:2,totalDimensionsCites:4,book:{slug:"bioethanol",title:"Bioethanol",fullTitle:"Bioethanol"},signatures:"Hua Song",authors:[{id:"38731",title:"Dr.",name:"Hua",middleName:null,surname:"Song",slug:"hua-song",fullName:"Hua Song"}]},{id:"27349",title:"Single-Step Bioconversion of Unhydrolyzed Cassava Starch in the Production of Bioethanol and Its Value-Added Products",slug:"single-step-bioconversion-of-unhydrolyzed-cassava-starch-in-the-production-of-bioethanol-and-its-val",totalDownloads:5764,totalCrossrefCites:0,totalDimensionsCites:3,book:{slug:"bioethanol",title:"Bioethanol",fullTitle:"Bioethanol"},signatures:"Azlin Suhaida Azmi, Gek Cheng Ngoh, Maizirwan Mel and Masitah Hasan",authors:[{id:"39139",title:"Ms",name:"Azlin",middleName:null,surname:"Azmi",slug:"azlin-azmi",fullName:"Azlin Azmi"},{id:"50515",title:"Dr.",name:"Gek Cheng",middleName:null,surname:"Ngoh",slug:"gek-cheng-ngoh",fullName:"Gek Cheng Ngoh"},{id:"50516",title:"Prof.",name:"Maizirwan",middleName:null,surname:"Mel",slug:"maizirwan-mel",fullName:"Maizirwan Mel"},{id:"99594",title:"Prof.",name:"Masitah",middleName:null,surname:"Hasan",slug:"masitah-hasan",fullName:"Masitah Hasan"}]},{id:"27354",title:"Bioethanol Production from Steam Explosion Pretreated Straw",slug:"bioethanol-production-from-steam-explosion-pretreated-straw",totalDownloads:3512,totalCrossrefCites:2,totalDimensionsCites:4,book:{slug:"bioethanol",title:"Bioethanol",fullTitle:"Bioethanol"},signatures:"Heike Kahr, Alexander Jäger and Christof Lanzerstorfer",authors:[{id:"41412",title:"Dr.",name:"Christof",middleName:null,surname:"Lanzerstorfer",slug:"christof-lanzerstorfer",fullName:"Christof Lanzerstorfer"},{id:"133428",title:"Dr.",name:"Alexander",middleName:null,surname:"Jäger",slug:"alexander-jager",fullName:"Alexander Jäger"},{id:"133430",title:"Dr.",name:"Heike",middleName:null,surname:"Kahr",slug:"heike-kahr",fullName:"Heike Kahr"}]},{id:"27353",title:"Second Generation Bioethanol from Lignocellulosics: Processing of Hardwood Sulphite Spent Liquor",slug:"second-generation-bioethanol-from-lignocellulosics-processing-of-hardwood-sulphite-spent-liquor",totalDownloads:4737,totalCrossrefCites:1,totalDimensionsCites:11,book:{slug:"bioethanol",title:"Bioethanol",fullTitle:"Bioethanol"},signatures:"Daniel L. A. Fernandes, Susana R. Pereira, Luísa S. Serafim, Dmitry V. Evtuguin and Ana M. R. B. Xavier",authors:[{id:"53912",title:"Prof.",name:"Ana",middleName:"Maria Rebelo Barreto",surname:"Xavier",slug:"ana-xavier",fullName:"Ana Xavier"},{id:"57360",title:"Dr.",name:"Daniel L.A.",middleName:null,surname:"Fernandes",slug:"daniel-l.a.-fernandes",fullName:"Daniel L.A. Fernandes"},{id:"57361",title:"MSc.",name:"Susana R.",middleName:null,surname:"Pereira",slug:"susana-r.-pereira",fullName:"Susana R. Pereira"},{id:"57362",title:"Dr.",name:"Luísa",middleName:null,surname:"Serafim",slug:"luisa-serafim",fullName:"Luísa Serafim"},{id:"57363",title:"Prof.",name:"Dmitry",middleName:null,surname:"Evtyugin",slug:"dmitry-evtyugin",fullName:"Dmitry Evtyugin"}]},{id:"27355",title:"Towards Increasing the Productivity of Lignocellulosic Bioethanol: Rational Strategies Fueled by Modeling",slug:"towards-increasing-the-productivity-of-lignocellulosic-bioethanol-rational-strategies-fueled-by-mode",totalDownloads:1533,totalCrossrefCites:0,totalDimensionsCites:5,book:{slug:"bioethanol",title:"Bioethanol",fullTitle:"Bioethanol"},signatures:"Hyun-Seob Song, John A. Morgan and Doraiswami Ramkrishna",authors:[{id:"56461",title:"Dr.",name:"Hyun-Seob",middleName:null,surname:"Song",slug:"hyun-seob-song",fullName:"Hyun-Seob Song"},{id:"57444",title:"Prof.",name:"John",middleName:null,surname:"Morgan",slug:"john-morgan",fullName:"John Morgan"},{id:"57447",title:"Prof.",name:"Doraiswami",middleName:null,surname:"Ramkrishna",slug:"doraiswami-ramkrishna",fullName:"Doraiswami Ramkrishna"}]},{id:"27356",title:"Consolidated Bioprocessing Ethanol Production by Using a Mushroom",slug:"consolidated-bioprocessing-ethanol-production-by-using-a-mushroom",totalDownloads:3401,totalCrossrefCites:2,totalDimensionsCites:4,book:{slug:"bioethanol",title:"Bioethanol",fullTitle:"Bioethanol"},signatures:"Satoshi Kaneko, Ryoji Mizuno, Tomoko Maehara and Hitomi Ichinose",authors:[{id:"38945",title:"Dr.",name:"Satoshi",middleName:null,surname:"Kaneko",slug:"satoshi-kaneko",fullName:"Satoshi Kaneko"},{id:"56886",title:"Dr.",name:"Ryoji",middleName:null,surname:"Mizuno",slug:"ryoji-mizuno",fullName:"Ryoji Mizuno"},{id:"56887",title:"Dr.",name:"Tomoko",middleName:null,surname:"Maehara",slug:"tomoko-maehara",fullName:"Tomoko Maehara"},{id:"56888",title:"Ms",name:"Hitomi",middleName:null,surname:"Ichinose",slug:"hitomi-ichinose",fullName:"Hitomi Ichinose"}]}],onlineFirstChaptersFilter:{topicSlug:"environmental-sciences-environmental-management-biofuels",limit:3,offset:0},onlineFirstChaptersCollection:[],onlineFirstChaptersTotal:0},preDownload:{success:null,errors:{}},aboutIntechopen:{},privacyPolicy:{},peerReviewing:{},howOpenAccessPublishingWithIntechopenWorks:{},sponsorshipBooks:{sponsorshipBooks:[{type:"book",id:"10176",title:"Microgrids and Local Energy Systems",subtitle:null,isOpenForSubmission:!0,hash:"c32b4a5351a88f263074b0d0ca813a9c",slug:null,bookSignature:"Prof. Nick Jenkins",coverURL:"https://cdn.intechopen.com/books/images_new/10176.jpg",editedByType:null,editors:[{id:"55219",title:"Prof.",name:"Nick",middleName:null,surname:"Jenkins",slug:"nick-jenkins",fullName:"Nick Jenkins"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:8,limit:8,total:1},route:{name:"profile.detail",path:"/profiles/297544/alfredo-g.-baez-melendres",hash:"",query:{},params:{id:"297544",slug:"alfredo-g.-baez-melendres"},fullPath:"/profiles/297544/alfredo-g.-baez-melendres",meta:{},from:{name:null,path:"/",hash:"",query:{},params:{},fullPath:"/",meta:{}}}},function(){var e;(e=document.currentScript||document.scripts[document.scripts.length-1]).parentNode.removeChild(e)}()